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Fibroblast growth factor (FGF) signaling pathways are es-
sential regulators of vertebrate skeletal development.
FGF signaling regulates development of the limb bud
and formation of the mesenchymal condensation and
has key roles in regulating chondrogenesis, osteogenesis,
and bone and mineral homeostasis. This review updates
our review on FGFs in skeletal development published
in Genes & Development in 2002, examines progress
made on understanding the functions of the FGF signaling
pathway during critical stages of skeletogenesis, and ex-
plores themechanisms bywhichmutations in FGF signal-
ing molecules cause skeletal malformations in humans.
Links between FGF signaling pathways and other interact-
ing pathways that are critical for skeletal development
and could be exploited to treat genetic diseases and repair
bone are also explored.
Skeletal development: an overview
Development of the vertebrate skeleton occurs through
the processes of endochondral and intramembranous
bone formation. Endochondral-derived bones comprise
the appendicular skeleton, facial bones, vertebrae, and
medial clavicles, while intramembranous bones comprise
the cranium and lateral clavicles. Endochondral ossifica-
tion initiates with the condensation of mesenchyme, fol-
lowed by the formation of a cartilaginous template that
patterns the developing skeleton and the segmentation
of this template into cartilaginous joints that are stabi-
lized by a flexible fibrous capsule andmineralized cortical
and trabecular (spongy) bone. Intramembranous bone
forms from a mesenchymal condensation that directly
gives rise to bone.
Chondrogenesis
Mesenchymal condensations are the first histologically
visible features of the developing appendicular skeleton
(Fig. 1A). Mesenchymal condensations form in the devel-
oping limb bud and are characterized by the aggregation of
loosemesenchymal cells and the expression of extracellu-
larmatrix proteins, cell adhesionmolecules, transcription
factors, and receptors for signaling molecules. The tran-
scription factor Sox9 is required for the differentiation
of the chondrogenic lineage, and bone morphogenetic
protein (BMP) receptors 1a and 1b are required for chon-
drogenesis and the maintenance of Sox9 expression (Ko-
sher et al. 1986; Nah et al. 1988; Bi et al. 1999; Akiyama
et al. 2002; Yoon et al. 2005; Yeung Tsang et al. 2014;
Lim et al. 2015). Proliferating cells within the forming
mesenchymal condensation express type II collagen
(Col2a1) centrally in chondroprogenitors and type I colla-
gen (Col1a1) peripherally in osteoprogenitors (Kosher
et al. 1986).
Proliferating chondrocytes form columns oriented
along the longitudinal axis of the developing bone. Mid-
way along the longitudinal axis of the mesenchymal con-
densation, proliferating chondrocytes exit the cell cycle
and differentiate into prehypertrophic chondrocytes (Fig.
1B,C) that are marked by expression of Indian Hedgehog
(IHH), parathyroid hormone (PTH)-related peptide recep-
tor (PTH1R), and type X collagen (Col10a1). Several tran-
scription factors are required for the initiation and
progression of chondrocyte hypertrophy. Sox9 is required
to maintain chondrocyte identity and prepare chondro-
cytes for subsequent hypertrophy but must be down-regu-
lated for progression to hypertrophy (Ikegami et al. 2011;
Dy et al. 2012). Runx2 (Cbfa1) and Runx3 (Cbfa3) are re-
quired for chondrocyte maturation and indirectly func-
tion to enhance chondrocyte proliferation through
promoting Ihh expression (Yoshida et al. 2004). The bal-
ance between chondrocyte proliferation and hypertrophy
is regulated by interactions between several signaling
pathways, including IHH, PTH-related peptide (PTHLH),
BMP, Wnt, and fibroblast growth factor (FGF) (Long and
Ornitz 2013; Kozhemyakina et al. 2015). The activity of
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Wnt and PTHLH signals regulates the level of calcium/
calmodulin-dependent protein kinase II (CAMK2), which
induces chondrocyte hypertrophy in part through increas-
ing RUNX2 and β-catenin activity (Li et al. 2011; Long and
Ornitz 2013). Chondrocyte hypertrophy leads to an expan-
sive force that is required for bone elongation (Hunziker
et al. 1987; Hunziker and Schenk 1989; Noonan et al.
1998). Hypertrophic chondrocytes can also begin to min-
eralize their extracellular matrix and have the capacity
to differentiate into osteoblasts within the primary spon-
giosa (Yang et al. 2014; Zhou et al. 2014).
Endochondral bone formation
Mineralized bone originates with the establishment of a
primary ossification center (Fig. 1D) that initiates with
the differentiation of type I collagen-producing osteo-
blasts and the formation of a bone collar (the precursor
of cortical and trabecular bone) surrounding the central
hypertrophic chondrocyte zone. Lineage tracing studies
show that osteoprogenitor cells (Osterix lineage) in the
perichondrium/periosteum give rise to trabecular osteo-
blasts, while more mature osteoblasts (Collagen I lineage)
remain in the perichondrium and populate cortical bone
(Maes et al. 2010). Vascular endothelial growth factor
(VEGF-A), expressed in hypertrophic chondrocytes, sup-
ports the invasion of endothelial cells, osteoprogenitor
cells, and osteoclasts, which remodel the chondrogenic
matrix and organize to form the primary ossification cen-
ter (Liu and Olsen 2014). Bidirectional expansion of the
primary ossification center along the longitudinal axis re-
places growth plate chondrocytes with trabecular bone
(primary spongiosa). After formation of a secondary ossifi-
cation center within the distal resting chondrocyte zone,
the definitive growth plate can be identified by well-de-
marcated zones of cells (Fig. 1E,F). Toward the epiphysis
Figure 1. Fibroblast growth factor (FGF) and FGF re-
ceptor (FGFR) expression patterns during endochon-
dral bone development. (A–D) Progression of
endochondral bone development from themesenchy-
mal condensation to formation of the primary ossifi-
cation center. (E) Embryonic growth plate. (F )
Postnatal growth plate after formation of the second-
ary ossification center. (G) Developmental progres-
sion of intramembranous bone development. Cells
and tissues are color-coded for expression domains
of FGFs and FGFRs. (BM) Bone marrow.
Ornitz and Marie
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of a developing bone, slowly growing resting chondrocytes
and cells within the adjacent groove of Ranvier and ring of
LaCroix serve as a pool of progenitor cells that populate
the rapidly dividing cells within the proliferating chondro-
cyte zone, which differentiate into prehypertrophic and
then hypertrophic chondrocytes (Robinson et al. 1999;
Abad et al. 2002; Karlsson et al. 2009). At the distal end
of the epiphyseal growth plate (toward the midpoint of a
long bone), hypertrophic chondrocytes either die by apo-
ptosis or differentiate into trabecular osteoblasts (Yeung
Tsang et al. 2014). Continued growth of the vascular net-
work and influx of hematopoietic-derived cells, including
osteoclasts, remodels the primary spongiosa to form the
bone marrow cavity.
Intramembranous bone formation
During development, intramembranous ossification be-
gins with the condensation of mesenchymal cells and
their progressive differentiation into osteoblasts to form
a mineralized matrix within ossification centers (Hall
and Miyake 2000). In the skull, these centers expand dur-
ing development but do not fuse at the junctionwith other
cranial bones, allowing skull expansion during growth
(Opperman 2000). The junction between cranial bones,
called a suture, is responsible for the maintenance of sep-
aration between two membrane bones. Most cells sur-
rounding the suture are mesenchymal cells, a minority
of which differentiate into preosteoblasts and then into
mature osteoblasts, which are found along the developing
bone trabeculae. At the end of the bone formation period,
osteoblasts die by apoptosis or become embedded in the
matrix as osteocytes, which then eventually also undergo
apoptosis (Fig. 1G; Rice et al. 1999; Fromigue et al. 2005).
The early commitment of mesenchymal stem cells into
osteoblasts requires expression of Runx2, a master tran-
scription factor that regulates several genes in osteoblasts,
such as type I collagen, bone sialoprotein (BSP), osteopon-
tin (OP), transforming growth factor (TGFβ), and osteocal-
cin (OC) (Marie 2008). Transcription factors, such as
MSX2 andDLX5, play important roles in osteoblast differ-
entiation during cranial bone formation in part by inter-
acting with RUNX2 (Dailey et al. 2005; Rice and Rice
2008). The regulation of intramembranous bone forma-
tion involves several regulatory factors, including TGFβs,
BMPs, FGFs, and Wnt signaling, all of which were shown
to regulate cell differentiation and survival in a spatiotem-
poral manner (Opperman 2000; Dailey et al. 2005; Lenton
et al. 2005; Rice and Rice 2008).
FGF signaling
The canonical and endocrine branches of the mammalian
FGF family comprise 18 secreted signaling proteins that
bind to and activate four receptor tyrosine kinase mole-
cules (FGF receptors [FGFRs]) (Ornitz and Itoh 2015). Fif-
teen canonical FGFs are differentially expressed in most
tissues of the developing embryo, where they function
as essential regulators of the earliest stages of devel-
opment and organogenesis. Canonical FGFs are also
expressed in postnatal and adult tissues, where they regu-
late growth and function as factors for tissue mainte-
nance, repair, and regeneration. Three endocrine FGFs
have critical postnatal roles in the regulation of phos-
phate, bile acid, carbohydrate, and lipid metabolism.
Of the four tyrosine kinase FGFRs, FGFR1, FGFR2, and
FGFR3 undergo alternative splicing to produce variants
that have distinct ligand-binding specificities and that
are differentially expressed in epithelial and mesenchy-
mal lineages. In general, FGFRb splice variants are found
in epithelial tissues and bind FGFs such as FGF7 and
FGF10 that are expressed inmesenchymal tissues. FGFRc
splice variants are found inmesenchymal tissues and bind
FGF ligands that are expressed in both epithelial and mes-
enchymal lineages. A fifth nontyrosine kinase FGFR,
FGFR5 or FGFRL1, is homologous to FGFR1–4 in the
extracellular ligand-binding domain but lacks an intracel-
lular tyrosine kinase domain. Fgfrl1was originally identi-
fied in human cartilage (Wiedemann and Trueb 2000).
The biological activity of canonical FGFs is enhanced
by heparan sulfate (HS) and other sulfated polysaccharides
(Shimokawa et al. 2011; Ornitz and Itoh 2015). A class of
cell surface and extracellular matrix proteins primarily
consisting of HS proteoglycans (HSPGs) contain HS cova-
lently attached to a protein core. HSPGs include cell sur-
face transmembrane proteins (syndecans), cell surface
glycerophosphatidylinositide-anchored proteins (glypi-
cans), and diffusible protein components of the extracellu-
lar matrix (perlecan and agrin) (Ornitz and Itoh 2015). Cell
surface and extracellular matrix HSPGs affect diffusion of
FGFs in tissues and interact with FGFs and FGFRs to in-
crease the affinity of FGF–FGFR heterodimers to enhance
receptor activation (Wu et al. 2003; Belov and Moham-
madi 2013; Xu and Esko 2014). In contrast to canonical
FGFs, endocrine FGFs require a protein cofactor to en-
hance receptor binding and activation. Members of the
Klotho family were found to fulfill this role based on phe-
notypic similarities of αKlotho and Fgf23 knockout mice
(Kurosu et al. 2006; Urakawa et al. 2006; Kuro-o 2008).
Binding of FGF ligands to FGFRs induces dimerization
and juxtaposition of the tyrosine kinase domains to
initiate the sequential transphosphorylation of at least
six tyrosine residues (Furdui et al. 2006; Goetz and
Mohammadi 2013; Ornitz and Itoh 2015). Activation of
the FGFR tyrosine kinase domain allows the direct phos-
phorylation of the docked adaptor protein FGFR substrate
2α (FRS2α) and binding of other adaptor proteins, includ-
ing phospholipaseCγ (PLCγ), signal transducer and activa-
tor of transcription 1 (STAT1), STAT3, and STAT5 (Ornitz
and Itoh 2015). In chondrocytes, FGFR3 has been found to
specifically activate STAT1 (Su et al. 1997; Sahni et al.
1999). Phosphorylation of FRS2α recruits the adaptor pro-
tein GRB2, which activates the MAPK pathway thorough
SOS and the PI3K–AKT pathway through GAB1 (Kouhara
et al. 1997; Lamothe et al. 2004). Downstream from RAS
and PI3K, FGFs can activate several distinct MAPKs, in-
cluding ERK1/2, JNK, and p38 (Tan et al. 1996; Tsang
and Dawid 2004; House et al. 2005; Liao et al. 2007; Kana-
zawa et al. 2010). Binding of CRKL to the activated FGFR
FGF signaling in skeletal development and disease
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enhances phosphorylation of FRS2α, MAPK pathway sig-
naling, and ERK1/2 activation (Moon et al. 2006).
The four known branches of the FGFR intracellular sig-
naling cascades are also regulated by inhibitorymolecules
that include high-level expression of GRB2 (which inter-
feres with PLCγ binding to the FGFR) and Sprouty (Spry)
proteins (which interact with GRB2 to block MAPK
and PI3K signaling) (Hanafusa et al. 2002; Timsah et al.
2014). Further downstream, SEF (similar expression to
FGF) antagonizes theMAPK pathway through interaction
with MEK (Torii et al. 2004), and DUSP6 (dual-specificity
phosphatase 6) suppresses MAPK signaling through de-
phosphorylation of ERK1/2 (Camps et al. 1998). The
E3 ubiquitin ligase CBL inhibits FGFR signaling by
forming a ternary complex with phospho-FRS2 and
GRB2, where it promotes the ubiquitination and degra-
dation of the FGFR and FRS2 (Wong et al. 2002). CBL
also interacts with PI3K, leading to its ubiquitination
and degradation (Dufour et al. 2008). The adaptor pro-
tein Grb14 binds to FGFR phospho-Tyr766 and inter-
feres with phosphorylation and activation of PLCγ
(Browaeys-Poly et al. 2010).
FGF signaling during skeletal development
The endochondral mesenchymal condensation
Fgfs, Fgfrs, and their co-receptor, HS, are expressed in a
time- and space-dependent manner during all stages of
skeletal development (Fig. 1). At precondensation stages,
distal limb bud mesenchyme expresses both Fgfr1 and
Fgfr2 (Orr-Urtreger et al. 1991; Sheeba et al. 2010), where-
as Fgfr3 and Fgfr4 are not detected in undifferentiated dis-
tal limb budmesenchyme (Sheeba et al. 2010). Distal limb
bud FGFRs respond to FGFs produced by the apical ecto-
dermal ridge (AER) of the limb bud (Zeller et al. 2009).
AER FGFs (primarily FGF4 and FGF8) signal to limb mes-
enchyme and are required for proximo–distal outgrowth
of the limb bud. The function of mesenchymal FGFRs in
the limb bud has been investigated through conditional
gene inactivation using the Cre/LoxP system and by ex-
pressing inhibitory RNAs. Conditional inactivation of
Fgfr1 and Fgfr2 in limb bud mesenchyme (using Prx1-
Cre) or inactivation of Fgfr1 in all mesenchyme [using T
(brachyury)-Cre] results in severe skeletal hypoplasia
(Verheyden et al. 2005; Yu and Ornitz 2008). In contrast,
inactivation of Fgfr1 or Fgfr2 in distal limb bud mesen-
chyme (using AP2-Cre) results in considerably milder
skeletal patterning phenotypes (Coumoul et al. 2005; Li
et al. 2005). These experiments collectively demonstrate
redundancy between FGFR1 and FGFR2 in distal limb
mesenchyme.
In condensingmesenchyme (Fig. 1A) Fgfr2 expression is
increased (compared with the surrounding mesenchyme)
and initially overlaps with domains of Sox9 expression
(Orr-Urtreger et al. 1991; Peters et al. 1992; Szebenyi
et al. 1995; Delezoide et al. 1998; Eswarakumar et al.
2002; Sheeba et al. 2010). Fgfr1 is more uniformly ex-
pressed throughout limb bud mesenchyme. Although
Fgfr3 and Fgfr4 are excluded from distal limb bud mesen-
chyme, these Fgfrs are expressed in more proximal loca-
tions in tissues corresponding to developing muscle (Orr-
Urtreger et al. 1991; Peters et al. 1992; Szebenyi et al.
1995; Delezoide et al. 1998; Sheeba et al. 2010). Cells
in the periphery of the condensation that will form peri-
chondrium and periosteum express both Fgfr1 and Fgfr2
(Fig. 1B–D; Delezoide et al. 1998; Eswarakumar et al.
2002). As soon as condensed mesenchyme begins to
differentiate into chondrocytes, Fgfr3 expression is acti-
vated (Fig. 1B) along with Sox9 and type II collagen, and
Fgfr2 expression is decreased (Peters et al. 1992, 1993; Pur-
cell et al. 2009).As central chondrocytes begin tohypertro-
phy, Fgfr3 expression is decreased, and Fgfr1 expression is
increased (Fig. 1C; Peters et al. 1992, 1993; Deng et al.
1996; Naski et al. 1998; Jacob et al. 2006; Karolak et al.
2015).
The initiation of the mesenchymal condensation and
its differentiation to the chondrogenic lineage are at least
partially dependent on FGFR signaling (Murakami et al.
2000; Mariani et al. 2008; Yu and Ornitz 2008; Kumar
and Lassar 2014). In primary chondrocytes and undifferen-
tiated mesenchymal cell lines, FGF signaling increases
Sox9 expression (Murakami et al. 2000; Shung et al.
2012). FGF activation of ERK1/2 also maintains compe-
tence of limb budmesenchyme to differentiate into chon-
drocytes by blocking Wnt-induced methylation and
silencing of the Sox9 promoter (Ten Berge et al. 2008;
Kumar and Lassar 2014). Fgfr3 expression in proliferating
chondrocytes requires Sox9, and Sox9-binding sites are
found in the Fgfr3 gene (Oh et al. 2014). FGFR3 signaling
is mitogenic for immature proliferating chondrocytes
and is likely activated by FGF9 and FGF18, which are ex-
pressed in adjacent mesenchyme (Fig. 1; Iwata et al. 2000,
2001; Liu et al. 2002, 2007; Ohbayashi et al. 2002; Hung
et al. 2007; Havens et al. 2008).
The forming perichondrium, bone collar, and trabecular
bone express FGFR1 in mesenchymal progenitors and
FGFR2 in differentiating osteoblasts (Fig. 1E,F; Molteni
et al. 1999b; Britto et al. 2001; Ohbayashi et al. 2002; Jacob
et al. 2006; Coutu et al. 2011). FGFR3 is expressed more
intensely in chondroprogenitor cells located in the groove
of Ranvier and ring of LaCroix (Robinson et al. 1999), and
FGFR1 and FGFR3 are expressed in mouse and human ar-
ticular chondrocytes (Fig. 1F; Yan et al. 2011; Weng et al.
2012). Immature cultured osteoblasts in vitro expressed
relatively higher levels of Fgfr1, whereas mature osteo-
blasts express relatively higher levels of Fgfr2 (Rice et al.
2003). Differential expression of these Fgfrsmay reflect a
distinct response to exogenous FGFs such as FGF2
(Cowan et al. 2003).
Intramembranous mesenchymal condensations
The spatiotemporal pattern of expression of Fgfs and Fgfrs
that control FGF signaling during membranous bone for-
mation is reviewed in Ornitz and Marie (2002). Fgf2,
Fgf4, Fgf9, Fgf18, Fgfr1, Fgfr2, and Fgfr3 are expressed
throughout the early stages of intramembranous bone de-
velopment (Fig. 1G; Kim et al. 1998; Rice et al. 2000;
Britto et al. 2001; Liu et al. 2002; Ohbayashi et al. 2002;
Ornitz and Marie
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Quarto et al. 2009). The FGFR2c splice variant is ex-
pressed in early mesenchymal condensations and then
in sites of intramembranous ossification, where it in-
teracts with FGF18 (Eswarakumar et al. 2002). At later
stages during cranial bone development, Fgf18 is ex-
pressed in mesenchymal cells and differentiating osteo-
blasts (Ohbayashi et al. 2002; Reinhold and Naski 2007).
Fgf9 is expressed throughout calvarial mesenchyme dur-
ing mid to late stages of embryonic development (Kim
et al. 1998). Mice lacking both Fgf9 and Fgf18 have severe-
ly deficient cranial bone formation (IH Hung, CG Schoen-
wolf, M Lewandoski, and DM Ornitz, in prep.). Fgfr1 and
Fgfr2, which are expressed in preosteoblasts and osteo-
blasts (Rice et al. 2003), are likely receptors for FGF9
and FGF18 in developing membranous bone. (Ornitz and
Marie 2002)
The growth plate
Growth plate chondrocytes express very low levels of
Fgfr2 in the resting zone, high levels of Fgfr3 in the prolif-
erating and prehypertrophic zone, and high levels of Fgfr1
in hypertrophic chondrocytes (Fig. 1E,F; Peters et al. 1993;
Delezoide et al. 1998; Hamada et al. 1999; Eswarakumar
et al. 2002; Ornitz and Marie 2002; Yu et al. 2003; Jacob
et al. 2006; Lazarus et al. 2007; Karolak et al. 2015). To in-
vestigate the potential functions of FGFR2 in skeletal de-
velopment, the Fgfr2 gene was conditionally inactivated
in limb bud mesenchyme with Dermo1(Twist2)-Cre (Yu
et al. 2003). Although these mice showed decreased post-
natal growth, chondrocyte proliferation and the length of
the proliferating chronfrocyte zone were not affected,
suggesting that FGFR2 does not have a nonredundant
function in resting or proliferating chondrocytes. The re-
duced stature of these mice was attributed to decreased
osteogenesis and increased osteoclast activity at the chon-
dro–osseous junction (Yu et al. 2003).
In early embryonic stages of skeletal development, dur-
ing establishment of the growth plate, FGFR3 has promi-
togenic activity in chondrocytes (Iwata et al. 2000, 2001;
Havens et al. 2008). However, following formation of the
secondary ossification center and throughout postnatal
skeletal growth, FGFR3 signaling functions to inhibit
chondrogenesis, primarily acting on proliferating chon-
drocytes and their differentiation to prehypertrophic and
hypertrophic chondrocytes (Colvin et al. 1996; Deng
et al. 1996). This paradoxical activity of FGFR3 underlies
the etiology of chondrodysplastic disorders in which gain-
of-function mutations in FGFR3 cause decreased prolifer-
ation and differentiation of proliferating chondrocytes
during prepubertal skeletal growth, resulting in skeletal
dwarfism (Naski et al. 1996, 1998). The mechanisms
that regulate FGFR3 expression and signaling during pre-
pubertal skeletal growth are an ongoing and important
topic of research. In addition to providing an understand-
ing of the mechanisms regulating bone growth, these
studies are providing potential therapeutic avenues for
the treatment of achondroplasia and other forms of skele-
tal dwarfism.
FGFR3 signaling in growth plate chondrocytes Signaling
through FGFR3 in growth plate chondrocytes activates
STAT1, ERK1/2, and p38 intracellular signals; increases
expression of Snail1 (Snai1); down-regulates AKT; acti-
vates protein phosphatase 2a (PP2a); and leads to dephos-
phorylation (activation) of the retinoblastoma family
members p107 and p130 (Fig. 2; Su et al. 1997; Laplantine
et al. 2002; Raucci et al. 2004; Priore et al. 2006; de Frutos
et al. 2007; Kolupaeva et al. 2008; Kurimchak et al. 2013).
Ultimately, suppression of chondrocyte proliferation
Figure 2. FGF signaling pathways in proliferating
chondrocytes. During endochondral bone develop-
ment, FGF9 and FGF18, derived from the perichondri-
um and surrounding tissue, signal to chondrocytes.
Activity is mediated in part by regulated diffusion
through the extracellular matrix through affinity for
HS and potentially other sulfated glycosaminogly-
cans. Activation of FGFR3 in proliferating chondro-
cytes activates the STAT1 and MAPK signaling
pathways. FGFR3 signaling results in increased ex-
pression of Snail1, which in turn is required for
STAT1 and MAPK signaling. FGFR3 signaling can
also activate PP2a. Activation of downstream signals,
p107, p21Waf1/Cip1, and Sox9 regulates chondrocyte
proliferation and differentiation to hypertrophic chon-
drocytes. C-type natriuretic peptide (CNP) signals
through the natriuretic peptide receptor 2 (NPR2), a
guanylyl cyclase. cGMP activates cyclic GMP-depen-
dent protein kinase II (cGKII), which, through p38
MAPK activation, functionally antagonizes RAF1 ac-
tivation of MEK. See the text for more details.
FGF signaling in skeletal development and disease
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resulting from activation of FGFR3 is effected through in-
creased expression of the cell cycle inhibitor p21Waf1/Cip1
and activation of p107 (and p130) (Cobrinik et al. 1996;
Su et al. 1997; Aikawa et al. 2001; Laplantine et al. 2002;
Dailey et al. 2003; Legeai-Mallet et al. 2004; Kolupaeva
et al. 2008, 2013).
SNAIL1 is integral to the FGFR3 signaling pathway in
chondrocytes (Fig. 2). Snail1 expression is induced by
FGFR3, and Snail1 is expressed at high levels in human
thantophoric dysplasia bone tissue. Experimentally,
ectopic activation of SNAIL1 in mice resulted in an
achondroplasia phenotype with decreased chondrocyte
proliferation and shortened bones at late embryonic stages
(de Frutos et al. 2007). Functionally, SNAIL1 appears to ac-
tivate both the STAT1 and MAPK branches of the FGFR3
signaling pathway, as ectopic activation of SNAIL1 result-
ed in nuclear translocation of STAT1 and increased phos-
phorylation of ERK1/2 (de Frutos et al. 2007). Although the
mechanism by which SNAIL1 regulates STAT1 and
MAPK is not known, a recent report showed that SNAIL1
may regulate the nuclear localization of p-ERK (Smith
et al. 2014). Conversely, activated ERK2 directly phos-
phorylates SNAIL1, leading to nuclear accumulation and
increased protein stability (Zhang et al. 2013). In support
of a requirement for SNAILproteins in regulating chondro-
genesis, conditional inactivation of both Snail1 and Snail2
resulted in increased p21Waf1/Cip1 and decreased chondro-
cyte proliferation (Chen and Gridley 2013).
Decreased bone growth, caused by activatingmutations
in FGFR3, results from decreased chondrocyte prolifera-
tion and decreased hypertrophy. The underlying mecha-
nisms suggest that these phenotypes are distinct and are
regulated by different branches of the FGFR3 signaling
pathway. Evidence that the STAT1 branch of the pathway
regulates chondrocyte proliferation is derived from in vivo
rescue experiments in which chondrocyte proliferation
defects in mice with activating mutations in FGFR3 can
be rescued by biallelic inactivation of Stat1 (Murakami
et al. 2004). However, in this model, inactivation of
Stat1 still does not rescue the overall achondroplasia phe-
notype in which impaired chondrocyte hypertrophy leads
to decreased bone growth. Further studies showed that,
downstream from FGFR3, activation of MAPK signaling
suppressed chondrocyte hypertrophy, resulting in skeletal
dwarfism (Murakami et al. 2004). Themechanismmay in-
volve suppression of SOX9 down-regulation in prehyper-
trophic chondrocytes by activated FGFR3 signaling (Fig.
2; Murakami et al. 2000; Shung et al. 2012; Zhou et al.
2015). Additionally, activation of the PP2A–B55α holoen-
zyme by FGFR3, which dephosphorylates and activates
p107, may independently contribute to decreased chon-
drocyte hypertrophy (Fig. 2; Kolupaeva et al. 2013; Kurim-
chak et al. 2013).
Further support of the model in which STAT1 activa-
tion suppresses chondrocyte proliferation and MAPK sig-
naling regulates matrix production and chondrocyte
differentiation is derived from studies that examined in-
teractions between FGFR3 and the C-type natriuretic pep-
tide (CNP) signaling pathways (Fig. 2; Yasoda et al. 2004).
CNP expression was found to attenuate the phenotype of
achondroplasia mice through inhibition of MAPK signal-
ing, which restored matrix production and hypertrophic
differentiation (see below). The activity of CNP was nota-
bly independent of STAT1 activity and did not affect
chondrocyte proliferation.
The function of the STAT1 and MAPK branches of the
FGFR3 signal pathway may not be completely distinct. In
cultured chondrocytes, FGFR3 suppression of chondro-
cyte proliferation required MAPK signaling and was inde-
pendent of STAT signaling (Raucci et al. 2004; Krejci et al.
2008a). In support of this observation, mice lacking ERK1
and conditionally lacking ERK2 (Col2a1-Cre) in chondro-
cytes showed increased chondrocyte proliferation at late
embryonic stages (Matsushita et al. 2009a; Sebastian
et al. 2011). Some of the variability in experimental results
may be due to in vitro culture conditions, the develop-
mental stage being examined (embryonic vs. postnatal),
and potential indirect effects on proliferating chondro-
cytes resulting from interactions with other signaling
pathways in nearby cells within the groove of Ranvier,
ring of LaCroix, and perichondrium.
Indirect mechanisms by which FGFR3 signaling may
regulate growth plate development include the regulation
of BMP, Wnt, IHH, and PTHLH/PTH1R expression and
activity. Comparisons of activating mutations in Fgfr3
andmice lacking Fgfr3 (Fgfr3−/−) show that FGFR3 signal-
ing suppresses expression of Bmp4, BMPR1a, Ihh, and
Pth1r in postnatal growth plate chondrocytes (Naski
et al. 1998; Chen et al. 2001; Qi et al. 2014). Additionally,
in a chondrocyte cell line, overexpression of FGFR3 sup-
presses expression of both Pthlh and its receptor, Pth1r
(Li et al. 2010), and, in chondrocyte cell lines and micro-
mass cultures, FGF signaling activates Wnt/β-catenin sig-
naling through phosphorylation of LRP6 and functions to
suppress hypertrophic differentiation (Krejci et al. 2012;
Buchtova et al. 2015).
Regulation of Fgfr3 expression Regulation of FGFR3 expres-
sion and activation is essential for chondrogenesis. In cul-
tured cells, thyroid hormone has been shown to inhibit
chondrocyte proliferation and promote chondrocyte hy-
pertrophy, activities that are similar to that of signaling
through FGFR3. Consistent with this observation, treat-
ment of cultured chondrocytes with thyroid hormone in-
creased Fgfr3 expression, and mice lacking thyroid
hormone receptor had decreased levels of Fgfr3 in growth
plate chondrocytes (Barnard et al. 2005). PTHLHmay also
regulate FGFR3 expression. Treatment of thantophoric
dysplasia mice with intermittent PTH injection partially
rescued the lethality and skeletal growth phenotype. In
cultured cells, PTH treatment inhibited phosphorylation
of FGFR3, suggesting that PTH may function in part
through regulation of FGFR3 signaling (Xie et al. 2012).
Additionally, analysis of the Fgfr3 promoter identified a
transcriptional regulatory element, CSRh, which was re-
pressed by PTH through a cAMP and protein kinase A
(PKA)-dependent mechanism (McEwen et al. 1999). A
third mechanism that could regulate FGFR3 is hypoxia,
a characteristic feature of growth plate chondrocytes. Al-
though this has not been investigated in chondrocytes,
Ornitz and Marie
1468 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
in bladder cancer cells, Fgfr3 expression was induced by
hypoxia in a transcriptional and HIF-1α-dependent man-
ner (Blick et al. 2013).
FGFR1 signaling in hypertrophic chondrocytes Fgfr1 is promi-
nently expressed in prehypertrophic and hypertrophic
chondrocytes (Fig. 1) and overlaps with Fgfr3 in prehyper-
trophic chondrocytes (Fig. 1). The functions of FGFR1 sig-
naling in hypertrophic chondrocytes are not entirely
understood due to imprecise genetic tools and difficulties
in distinguishing cell-autonomous functions in hypertro-
phic chondrocytes from activities in the adjacent peri-
chondrium and other tissues. Activating mutations in
FGFR1 that cause osteoglophonic dysplasia result in
severe dwarfism in humans (White et al. 2005); however,
an activating mutation in Fgfr1 in mice did not affect en-
dochondral ossification (Zhou et al. 2000). Possible func-
tions of FGFR1 signaling have been investigated in mice
through targeted inactivation of Fgfr1 (Col2a1-Cre or
Dermo1-Cre). At early stages of development, Fgfr1 condi-
tional knockout mice (Dermo1-Cre) show impaired chon-
drocyte hypertrophy (Hung et al. 2007). In contrast, at
later stages of development, Fgfr1 conditional knock-
out mice (Col2a1-Cre) have an expanded hypertrophic
chondrocyte zone (Jacob et al. 2006). Both Dermo1-Cre
and Col2a1-Cre efficiently target chondrocytes but also
target the osteoblast lineage (Yu et al. 2003; Jacob et al.
2006; Ford-Hutchinson et al. 2007; Wang et al. 2011; Ono
et al. 2014). Therefore, defects in osteoblast development
could indirectly affect chondrogenesis (Jacob et al. 2006;
Karolak et al. 2015), and a definitive assessment of
FGFR1 function in hypertrophic chondrocytes will thus
require more precise targeting of the chondrocyte lineage.
FGF ligands in endochondral bone growth Fgf9 and Fgf18 are
expressed in the perichondrium and periosteum, and
Fgf2 is expressed in chondrocytes (Gonzalez et al. 1996;
Liu et al. 2002; Ohbayashi et al. 2002; Hung et al. 2007;
Reinhold and Naski 2007). Mice lacking Fgf2 have de-
creased bonemass but no apparent change in growth plate
structure or function (Montero et al. 2000). In contrast,
mice lacking Fgf9 exhibit rhizomelic (affecting proximal
skeletal elements) shortening of the appendicular skele-
ton. FGF9 and FGF18 also have stage-specific effects on
chondrogenesis. At early stages of development of the hu-
merus and femur, chondrocyte proliferation is decreased,
and chondrocyte hypertrophy is impaired in Fgf9−/−mice
(Hung et al. 2007). Mice lacking Fgf18 show decreased
chondrocyte proliferation inmore distal skeletal elements
(Liu et al. 2007). This phenotype is consistent with FGF9
and FGF18 signaling to FGFR3 and the promitogenic prop-
erties of FGFR3 on immature chondrocytes (Iwata et al.
2000, 2001; Hung et al. 2007). At later stages of develop-
ment, Fgf9−/− and Fgf18−/− mice show an expansion of
the femoral hypertrophic chondrocyte zone, a phenotype
that is consistent with FGFR3 functioning to suppress
chondrocyte proliferation and differentiation in the ma-
ture growth plate (Liu et al. 2002; Ohbayashi et al. 2002;
Hung et al. 2007). In contrast to mice lacking Fgf9, mice
lacking Fgf18 (Fgf18−/−) have defects in chondrogenesis
that affect both proximal and distal skeletal elements.
Fgf18−/−mice also have defects in osteoblast proliferation
and differentiation that suggest signaling to FGFR1 and
FGFR2 in osteoprogenitor cells (discussed below). Mice
lacking both Fgf9 and Fgf18 have a severe osteochondro-
dysplasia that affects proximal and distal skeletal ele-
ments (IH Hung, CG Schoenwolf, M Lewandoski, and
DM Ornitz, in prep.).
Autosomal dominant mutations in FGF9 in both mice
andhumans affect chondrogenesis and formation of joints.
The elbow knee synostosis (EKS) mutation in mice and
the multiple synostosis syndrome in humans reduce the
affinity of FGF9 for its coreceptor, HS. Although reduced
affinity for HS impairs receptor binding, the resulting in-
creased diffusion of FGF9 through the extracellularmatrix
effectively increases its domain of activity in developing
chondrocytes and surrounding tissue (Harada et al. 2009;
Kalinina et al. 2009; Wu et al. 2009). The joint fusion phe-
notype is very similar to mice that cell-autonomously
overexpress an activated FGFR in developing chondro-
cytes (Wang et al. 2001).
Cortical, trabecular, and intramembranous bone
FGFR signaling in osteoblasts In cells of the osteoblast line-
age, FGFR-mediated activation of ERK1/2, PLCγ/PKCα,
and PI3K/Akt signaling results in the modulation of cell
proliferation, differentiation, and apoptosis, depending
on the stage of cell differentiation (Fig. 3; Dailey et al.
2005;Marie et al. 2005). In early osteoblast precursor cells,
activation of ERK1/2 by FGFR signaling primarily leads to
increased cell proliferation (Choi et al. 2008;Miraoui et al.
2009). In more mature cells, ERK1/2 activation by FGF2
enhances acetylation and stabilization of RUNX2, a key
transcription factor involved in osteoblastogenesis and
bone formation (Xiao et al. 2002; Park et al. 2010; Yoon
et al. 2014). ERK1/2 signaling is also involved inRunx2 ex-
pression and osteoblast differentiation induced by FGF18-
mediated activation of FGFR1/FGFR2 in murine osteo-
blast precursor cells (Hamidouche et al. 2010). PKCδ acti-
vation also plays a central role in FGF/FGFR-stimulated
expression and transactivation activity of RUNX2 (Kim
et al. 2003; Niger et al. 2013). In turn, RUNX2 enhances
the expression of Fgfr2, Fgf18, and proteoglycans that are
involved in FGF signaling in the perichondrium (Hinoi
et al. 2006; Reinhold and Naski 2007; Teplyuk et al.
2009). Finally, in an osteocyte cell line, FGF2-stimulated
ERK1/2 activation was found to increase the expression
of Dmp1, a marker of osteocytes. In vivo, Dmp1 expres-
sion is reduced in limbs of mice lacking ERK1 and condi-
tionally lacking ERK2 (Prx1-Cre), which show no
osteocytes, indicating that FGF signaling coordinately
regulates Dmp1 expression and osteocyte differentiation
(Kyono et al. 2012). Overall, these studies establish that
multiple pathways activated by FGF/FGFR signaling con-
trol all steps of osteoblastogenesis (Fig. 3).
FGFR signaling is down-regulated by negative feedback
mechanisms involving receptor internalization and degra-
dation (Schlessinger 2000; Lemmon and Schlessinger
FGF signaling in skeletal development and disease
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2010). This down-regulation process involves FGFR inter-
action with multiple proteins, including the docking pro-
tein FRS2α and the ubiquitin ligase c-CBL, an adaptor
protein that mediates FGFR ubiquitination after ligand
binding (Schmidt and Dikic 2005). In response to FGF
stimulation, tyrosine phosphorylation of FRS2α forms a
ternary complex with CBL and GRB2 (Schlessinger 2003).
Increased binding of activated FGFR2 to FRS2α and
c-CBL results in ubiquitination of the FGFR and its subse-
quent degradation by the proteasome (Schlessinger 2003).
Depending on the cell type, a proportion of the constitu-
tively activated FGFRs may be retained in intracellular
compartments and degraded following c-Cbl-dependent
ubiquitination (Hatch et al. 2006). In osteoblasts, CBL
plays an important role in down-regulation of activated
FGFR signaling and subsequently in the control of osteo-
blastogenesis (Severe et al. 2013). FGFR2 ubiquitination
by c-CBL leads to FGFR2 down-regulation and subsequent
reduction in osteogenic differentiation capacity, whereas
inhibition of c-CBL interaction with FGFR2 promotes os-
teoblast differentiation and osteogenic differentiation
through increased ERK1/2 and PI3K signaling (Dufour
et al. 2008). This highlights the essential role of c-CBL-me-
diated regulation of FGFR signaling in osteoblastogenesis
(Severe et al. 2013).
Interactionswith other pathways In addition to cell signaling
directly generated by activated FGF/FGFRs, FGF interacts
with other pathways, such as BMP signaling, to regulate
osteoblastogenesis. FGF2 treatment stimulates Bmp2
gene expression in osteoblasts during cranial bone ossifi-
cation (Choi et al. 2005; Fakhry et al. 2005). Consistently,
BMP2 expression is reduced in bones of Fgf2-null mice
(Naganawa et al. 2008). In line with this concept, BMP2
and FGF2 have a synergistic stimulatory effect on osteo-
genic function in human bone cells and in mice (Naka-
mura et al. 2005; Kuhn et al. 2013). Mechanistically,
FGF2 enhances canonical BMP2 signaling in osteoblasts
through promoting nuclear localization of RUNX2 and
phospho-SMAD1/5/8 (Agas et al. 2013). Moreover, FGF2
isoforms specifically modulate BMP2 function and osteo-
blast differentiation (Sabbieti et al. 2013), and FGF2, FGF9,
and FGF18 inhibit the expression of the BMP antagonist
Noggin in vitro and in vivo (Warren et al. 2003; Reinhold
et al. 2004; Fakhry et al. 2005). Thus, multiple mecha-
nisms mediate FGF and BMP signaling interactions, lead-
ing to regulation of osteoblast differentiation.
Genetic and functional evidence indicates that FGF
signaling functionally interacts with Wnt/β-catenin sig-
naling to control mesenchymal stem cell fate and differ-
entiation (Dailey et al. 2005; Miraoui and Marie 2010).
During cranial suture development, WNT/β-catenin sig-
naling controls stem cell renewal, proliferation, and line-
age specification by balancing the activity of the FGF and
BMP signaling pathways (Maruyama et al. 2010). Mecha-
nistically,WNT/β-catenin signaling induces Fgf18 expres-
sion through induction of a complex with RUNX2 and
TCF/LEF transcription factors on the Fgf18 promoter
(Fig. 3; Reinhold andNaski 2007). In osteoprogenitor cells,
FGF2 was found to antagonize WNT/β-catenin signaling
(Mansukhani et al. 2005; Ambrosetti et al. 2008). In vivo,
however, Wnt genes are decreased significantly in osteo-
blasts fromFgf2−/−mice,which display reducedosteoblast
differentiation (Fei et al. 2011). Consistentwith this, exog-
enous FGF2 can promote β-catenin nuclear accumulation
and rescue osteoblast differentiation in Fgf2−/−mice, indi-
cating that endogenous FGF2 stimulates cell differentia-
tion in more mature osteoblasts in part by activating
WNT/β-catenin signaling (Fei et al. 2011).
FGF signaling also interacts with the PTH signaling
pathway as PTH stimulates Fgf2, Fgfr1, and Fgfr2 in oste-
oblast cells (Hurley et al. 1999). Consistently, the anabolic
response to intermittent PTH is impaired in Fgf2-null or
heterozygousmice (Hurley et al. 1999). Functional studies
confirmed that endogenous FGF2 is required for the posi-
tive PTH effects on osteoblast proliferation, differen-
tiation, and survival, suggesting that the anabolic PTH
Figure 3. FGF/FGFR signaling in cells of the osteoblast lineage.
FGF9 and FGF18, expressed in periosteal and surrounding tissue,
interact with HS, FGFR1, and FGFR2. Activation of the FGFR ty-
rosine kinase domain leads to the recruitment of various sub-
strates and activation of phospholipase Cγ/PKCα, ERK MAPKs,
and PI3K/AKT, resulting in the modulation of transcription fac-
tors that control cell proliferation, differentiation, and survival
in cells of the osteoblast lineage. Following FGFR activation,
CBL is recruited and mediates FGFR ubiquitination and protea-
some degradation, leading to FGFR down-regulation. Activated
FGFRs may also be retained in intracellular compartments and
degraded following c-Cbl-dependent ubiquitination. FGFR signal-
ing activates expression of the transcription factor RUNX2,
which regulates the expression of osteoblast-specific genes. In co-
operation with Wnt/β-catenin signaling, RUNX2 activates Fgf18
gene expression. See the text for more details.
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effect is dependent in part on FGF2 expression (Sabbieti
et al. 2009). These genetic and functional analyses support
the concept that FGF/FGFR signaling by itself and its in-
teractions with other major signaling pathways play es-
sential roles in controlling osteoblastogenesis and bone
formation in adult life.
FGF and bone homeostasis
FGF/FGFR signaling in osteoblastogenesis
Bone formation is a complex process that involves the
commitment of mesenchymal cells that progressively dif-
ferentiate into osteoblast precursor cells and then into
mature bone-forming cells under the control of transcrip-
tion factors, systemic hormones, and local growth factors
aswell as cell–cell and cell–matrix interactions (Lian et al.
2006; Marie 2008; Long 2012). While it is well accepted
that FGF/FGFR signaling plays an important role in osteo-
blastogenesis, it is now clear that the effects in osteogenic
cells are complex, as they depend on the type of FGFs and
FGFRs expressed, the stage of cell maturation, and themi-
croenvironment (proteoglycans and interacting proteins)
thatmay either enhance or attenuate FGF/FGFR signaling
in bone cells. The collective data suggest that FGF2 signal-
ing increases cell proliferation in immature osteoblasts
and thereby expands the pool of osteoblast precursor cells
that then fully differentiate in the bone environment
(Debiais et al. 1998; Shimoaka et al. 2002; Ignelzi et al.
2003; Fakhry et al. 2005). Accordingly, blocking FGF2 bi-
ological activity reduces osteogenesis in vivo (Moore et al.
2002). Recent data indicate that FGF18 is also an essential
autocrine-positive regulator of the osteogenic differentia-
tion program (Jeon et al. 2012), mediated by FGFR1/
FGFR2 activation of ERK1/2 and PI3K signaling (Hami-
douche et al. 2010). Genetic studies in mice also demon-
strated that both FGF2 and FGF18 are important
regulators of skeletal cell proliferation and differentiation
during osteogenesis. Mice lacking Fgf2 display reduced
bone formation due to decreased osteoblast differentiation
(Montero et al. 2000; Xiao et al. 2010). Fgf18-deficient
mice show decreased osteogenic mesenchymal cell prolif-
eration, reduced osteoblast differentiation, and delayed
ossification (Liu et al. 2002; Ohbayashi et al. 2002). In ad-
dition to controlling osteoblast proliferation and differen-
tiation, FGF signaling regulates osteoblast apoptosis. In
osteoblast precursor cells, FGF2 induces osteoblast sur-
vival through activation of PI3K/AKT signaling (Debiais
et al. 1998) and FGFR1-mediated increased Bcl2/Bax ratio
(Agas et al. 2008). In more differentiated osteoblasts, FGF
treatment or overexpression of FGF2 in transgenic mice
induces apoptosis in mouse calvaria (Mansukhani et al.
2000; Ignelzi et al. 2003), which limits the increase in
the osteoblast population.
FGF regulation of bonemetabolism Recent data indicate that
some isoforms of FGF2 have distinct effects on bone me-
tabolism. Overexpression of the low-molecular-weight
(18-kDa) isoform of FGF2 in osteoblasts causes increased
trabecular and cortical bone mass resulting from in-
creased bone formation, whereas its inactivation results
in opposite effects, indicating that low-molecular-weight
FGF2 is a critical determinant of bone mass in mice
(Xiao et al. 2009). Mechanistic analysis showed that these
effects are related to modulation of the WNT/β-catenin
signaling pathway (Xiao et al. 2009). In contrast, overex-
pression of nuclear-localized high-molecular-weight
FGF2 isoforms in osteoblasts causes a phenotype similar
to X-linked hypophosphatemia (XLH), a disease character-
ized by increased expression of FGF23 by osteocytes.
FGF23 is a phosphaturic agent, and its overexpression
results in phosphate wasting, hypophosphatemia, and
rickets/osteomalacia. High-molecular-weight FGF2 over-
expression in osteoblast precursor cells results in the
inhibition of osteoblast differentiation and matrix miner-
alization through FGF23/FGFR/MAPK signaling, inde-
pendently of phosphate wasting (Xiao et al. 2013).
Conversely, genetic inactivation of the FGF2 high-molec-
ular-weight isoforms caused increased bone mass due to
increased osteoblast differentiation and decreased oscteo-
clast activity associated with decreased FGF23 expres-
sion, indicating a negative impact of high-molecular-
weight FGF2 isoforms on bone cell metabolism and phos-
phate homeostasis (Homer-Bouthiette et al. 2014). These
findings highlight the functional implications of distinct
FGF2 isoforms on FGF23 secretion, bone cell activity,
and bone matrix mineralization.
Functionally, the expression of FGF23 in osteoblasts
and osteocytes is controlled by FGFR1 signaling (Martin
et al. 2011), which in turn controls phosphate homeostasis
and bone mineralization (Quarles 2012; Feng et al. 2013).
Low-molecular-weight FGF2 stimulates FGF23 promot-
er activity through PLCγ/NFAT and MAPK signaling,
whereas high-molecular-weight FGF2 promotes FGF23
promoter activity through cAMP-dependent binding of
FGFR1 and CREB to a conserved cAMP response element
in the FGF23 promoter (Han et al. 2015). Consistently,
conditional deletion of Fgfr1 in osteocytes of Hyp mice,
a mouse model of XLH, reduced the excessive FGF23 lev-
els produced by osteocytes and partially rescued the bone
phenotype in these mice (Xiao et al. 2014). Moreover,
pharmacological activation of FGFR1 in osteoblasts leads
to increased FGF23 secretion and hypophosphatemia in
adult mice (Wu et al. 2013), whereas pharmacological
FGFR inhibition ameliorates FGF23-mediated hypophos-
phatemic rickets (Wohrle et al. 2013). These data support
an important role for FGF23/FGFR1 signaling in the con-
trol of bone mass and mineralization in vivo. The role of
FGF23 signaling in nonskeletal tissues and on phosphate
metabolism has been extensively reviewed (Quarles
2012; Liao 2013; White et al. 2014).
Stage-specific activity of FGFs in osteoblastogenesis FGFR
expression and function control cells of the osteoblast
lineage at different stages of differentiation. In mesenchy-
mal osteoprogenitor cells, FGFR1/2 are important for
maintaining mesenchymal stem cell stemness by inhibit-
ing cell senescence (Coutu et al. 2011; Di Maggio et al.
2012). During the osteogenic differentiation process, ini-
tially high Fgfr1/Fgfr2 expression is associated with
FGF signaling in skeletal development and disease
GENES & DEVELOPMENT 1471
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
FGF2 responsiveness and a robust proliferative response
(Cowan et al. 2003; Haupt et al. 2009). In more mature os-
teoblasts, decreased expression of Fgfr1 and increased ex-
pression of Fgfr2, Fgfr3, and Fgfr4 are associated with an
inability to sustain an FGF2 response (Haupt et al. 2009).
In vivo studies confirmed that FGFR1 controls osteoblasts
at different stages of maturation (Jacob et al. 2006). Condi-
tional inactivation of Fgfr1 in osteoprogenitor cells results
in increased proliferation and delayed differentiation and
matrix mineralization, whereas Fgfr1 deficiency in differ-
entiated osteoblasts caused enhanced mineralization and
increased expression of Fgfr3 (Jacob et al. 2006). FGFR2
also plays an important role in osteoblastogenesis. Inmes-
enchymal cells, constitutive Fgfr2 activation results in in-
creased osteoblast differentiation and decreased adipocyte
differentiation through ERK1/2 and PKCα signaling, re-
sulting in increased Runx2 expression (Miraoui et al.
2009, 2010b). Consistently, mice conditionally lacking
Fgfr2 or harboring amutation in Fgfr2c, themesenchymal
splice variant of Fgfr2, show decreased Runx2 expression,
retarded ossification, and decreased bonemineral density,
suggesting that Fgfr2 is a positive regulator of osteoblast
maturation (Eswarakumar et al. 2002; Yu et al. 2003).
Although FGFR3 is mainly expressed in chondrocytes,
young adult Fgfr3-null mice are osteopenic due to reduced
osteoblast maturation and defective trabecular bone min-
eralization, suggesting a role for FGFR3 in postnatal bone
metabolism (Valverde-Franco et al. 2004). Osteoblasts
derived from Stat1−/− mice have decreased expression of
Fgfr3 and increased expression of Fgf18, which acts
through FGFR1 or FGFR2, suggesting that changes in
the repertoire of Fgfr expression affects feedback loops
that control FGF-dependent osteoblastogenesis (Xiao
et al. 2004).
FGFs bind cell surface HSPGs, which serve as low-affin-
ity coreceptors that enhance FGF–FGFR binding and sig-
naling (Eswarakumar et al. 2005; Ornitz and Itoh 2015).
Early studies showed that some HSPGs, such as synde-
cans, expressed in the bone environment affect the osteo-
blast response to FGF2 during osteogenesis (Molteni et al.
1999a). In vitro data indicate that both cell surface and se-
creted HSPGs can further amplify FGF2 signaling and os-
teoblast differentiation (Jackson et al. 2007). Notably, the
HSPG glypican-3 was found to be essential for Runx2 ex-
pression and subsequent osteoblast differentiation in vitro
(Haupt et al. 2009). Since RUNX2 was found to enhance
the expression of FGFRs and proteoglycans such as synde-
cans in osteoblasts, RUNX2 and the FGF/proteoglycan
axis likely cooperate to control osteoblast proliferation
and differentiation (Fromigue et al. 2004; Teplyuk et al.
2009). Thus, the regulation of osteogenesis by FGF/
FGFR signaling is dependent on not only the expression
of a repertoire of FGFs and FGFRs but also the expression
of accessory extracellular molecules that regulate cell sig-
naling and FGF/FGFR biological activity.
FGF signaling in osteoclasts
Early studies suggested that FGF2 regulates bone resorp-
tion directly through its effect on osteoclast precursor pro-
liferation and indirectly by promoting prostaglandin G/H
synthase-2 (Ptgs2) expression and prostaglandin forma-
tion (Kawaguchi et al. 1995, 2000; Chikazu et al. 2001).
Additionally, FGF2 can act directly on mature osteoclasts
to stimulate bone resorption through the activation of
FGFR1 and MAPK (Chikazu et al. 2000; Kawaguchi
et al. 2000). A role for FGF2 in bone resorption is support-
ed by the finding that ostoclastogenesis in response to
PTH is markedly impaired in Fgf2-null mice (Okada
et al. 2003). FGF18 can also induce osteoclast formation
and function indirectly through stimulating receptor ac-
tivator of the nuclear factor-κB ligand (RANKL) and cyc-
looxygenase-2 expression in osteoblasts (Shimoaka et al.
2002). Another study showed that FGF6 increased the for-
mation and resorbing activity of human primary mature
osteoclasts in vitro (Bosetti et al. 2010), whereas FGF8a in-
hibited osteoclastogenesis, but not osteoclast function, in
mouse bone marrow cultures.
FGFR1 was detected on isolated mouse osteoclasts
(Chikazu et al. 2000). Osteoclasts with FGFR1 deficiency
(LysM-Cre mice) displayed decreased expression of genes
related to osteoclast activity, including TRAP and
MMP9, and exhibited abnormal bone remodeling with
reduced osteoclast number and impaired osteoclast func-
tion (Lu et al. 2009). On the other hand, osteoclast
numbers and bone resorption area were increased in cul-
tured bone marrow cells derived from Fgfr3G369C/+ mice,
suggesting that gain-of-function mutations in FGFR3 in-
crease osteoclast activity, which contributes to decreased
bone mass in these mice (Su et al. 2010).
Mutations in FGFRs in human skeletal disease
Mutations in FGFRs, first revealed with the discovery of
the genetic etiology of achondroplasia as a missense mu-
tation in FGFR3 (Shiang et al. 1994), highlight the impor-
tance of FGF signaling in skeletal development. Following
this initial discovery, many mutations have been identi-
fied in FGFR1–3 in related skeletal dwarfism syndromes,
craniosynostosis syndromes, and skeletal overgrowth syn-
dromes (Ornitz and Itoh 2015). The clinical and genetic
features of these diseases have been extensively reviewed
(Vajo et al. 2000; Ornitz and Marie 2002; Chen and Deng
2005; Marie et al. 2005; Ornitz 2005; Melville et al.
2010; Johnson and Wilkie 2011; Foldynova-Trantirkova
et al. 2012; Krejci 2014).
Chondrodysplasia syndromes
Achondroplasia is the most common form of skeletal
dwarfism in humans, and >97%of cases result from an au-
tosomal dominant missense mutation (G380R) in FGFR3
(Shiang et al. 1994;Wilkin et al. 1998; Vajo et al. 2000). Re-
lated autosomal dominant chondrodysplasia syndromes
include the more severe and usually lethal thanatophoric
dysplasia types I and II, which are attributed to two muta-
tions in FGFR3 (K650E and R248C, respectively), and the
milder form of dwarfism, hypochondroplasia, which is
caused by anN540K or K650Nmutation in FGFR3 (Bellus
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et al. 1995, 2000; Tavormina et al. 1995; Bonaventure et al.
1996). A closely related disease, referred to as severe
achondroplasia with developmental delay and acanthosis
nigricans (SADDAN) (Bellus et al. 1999; Tavormina et al.
1999), and a very rare lethal chondrodysplasia, platyspon-
dylic lethal skeletal dysplasia, SanDiego type (Brodie et al.
1999) are both caused by a K650Mmutation in FGFR3. A
dominant mutation (M528I) that causes proportionate
short stature was recently identified in FGFR3 (Kant
et al. 2015). Functional studies suggest that this mutation
is activating, similar to that of the G380R mutation that
causes achondroplasia; however, the mechanisms that
determine proportionate versus rhizomelic limb shorten-
ing are not known.
The mutations in FGFR3 associated with dwarfism ac-
tivate the receptor to varying degrees (Naski et al. 1996;
Krejci et al. 2008b). The N540K mutation causing hypo-
chondroplasia is a weak gain-of-function mutation, and
mutations causing achondroplasia and thantophoric dys-
plasia result in progressively stronger activation and, in
the case of the R248C mutation, ligand-independent con-
stitutive activation. FGFR3 is expressed prominently in
proliferating and prehypertrophic chondrocytes in the
growth plate, and activation of FGFR3 results in pheno-
types that include decreased chondrocyte proliferation,
impaired hypertrophic differentiation, and increased
apoptosis (discussed below; Legeai-Mallet et al. 1998,
2004; Naski et al. 1998; Wang et al. 1999, 2001; Krejci
et al. 2008b; Pannier et al. 2009).
The genetic homogeneity and relatively high incidence
of the achondroplasia G380Rmutation suggested that the
associated G1138A transition in FGFR3 might be one of
the most highly mutable nucleotides in the human ge-
nome (Wilkin et al. 1998; Vajo et al. 2000). However, the
paternal origin of the mutation and advanced paternal
age associated with achondroplasia suggested that a germ-
line selection model in which mutant spermatogonial
stem cells have a proliferative or survival advantage over
unmutated cells could better account for the observed pa-
ternal age effect (Dakouane Giudicelli et al. 2008; Shinde
et al. 2013). This paternal age effect also occurs with gain-
of-function mutations in FGFR2 that cause craniosynos-
tosis syndromes (Goriely et al. 2003, 2005; Goriely and
Wilkie 2012).
Skeletal overgrowth and camptodactyly, tall stature,
and hearing loss (CATSHL) syndrome
Inactivation of FGFR3 in mice results in skeletal over-
growth (Colvin et al. 1996; Deng et al. 1996; Eswarakumar
and Schlessinger 2007). Growth plate histology in mice
lacking Fgfr3 (Fgfr3−/−) showed an expanded proliferating
chondrocyte zone and hypertrophic chondrocyte zone be-
ginning at late stages of embryonic development and per-
sisting to adulthood. Bones of the appendicular skeleton
were disproportionally long compared with body weight,
and the mice developed elongation of vertebral bodies
and scoliosis. Fgfr3−/− mice also have primary defects in
inner ear development and are consequently deaf (Colvin
et al. 1996). The viability of Fgfr3−/−mice and the unique
combination of skeletal overgrowth and hearing loss phe-
notypes suggested that a similar condition resulting from
loss of function of FGFR3 could occur in humans. Analy-
sis of a four-generation family with dominantly inherited
CATSHL identified a missense mutation (R621H) in the
catalytic loop of the FGFR3 tyrosine kinase domain (Toy-
demir et al. 2006). This mutation inactivates the kinase
domain and likely confers dominant-negative activity to
the receptor. A homozygous mutation in the FGFR3 tyro-
sine kinase domain (T546K) has also been identified in
two siblings with CATSHL from consanguineous parents
(Makrythanasis et al. 2014). Interestingly, a similar reces-
sive mutation in FGFR3(V700E) in sheep results in spider
lamb syndrome, characterized by long limbs, kyphosco-
liosis, malformed ribs and sternebrae, Roman noses, lack
of body fat, and muscular atrophy (Beever et al. 2006).
Sheep that are heterozygous for this mutation appear nor-
mal but show a mild increase in skeletal growth (Smith
et al. 2006).
Craniosynostosis syndromes
Mutations in FGFR1, FGFR2, and FGFR3 cause skeletal
dysplasias (craniosynostosis) in Apert, Crouzon, and other
syndromes characterized by premature fusion of one or
more cranial sutures (Ornitz and Marie 2002; Johnson
and Wilkie 2011). Mutations in FGFRs also result in dys-
morphology of the appendicular skeleton, such as in
bent bone dysplasia, which is caused by a mutation in
FGFR2 (Merrill et al. 2012). The molecular mechanisms
that result from FGFRmutations are complex and include
constitutive (ligand-independent) or ligand-dependent
FGFR activation, loss of function, and altered cellular traf-
ficking of receptors (Yu et al. 2000; Ibrahimi et al. 2001; Yu
andOrnitz 2001; Neben et al. 2014). Genetic, cellular, and
molecular studies in mice and humans provided clues to
the abnormalities induced by gain-of-function FGFRmu-
tations (Hajihosseini 2008; Marie et al. 2008; Senarath-
Yapa et al. 2012). Specifically, Apert FGFR2(S252W) mu-
tations were shown to induce abnormal mesodermal pro-
genitor cell proliferation, differentiation, and cell fate in
cranial sutures in variousmousemodels, although the cel-
lular abnormalities vary among specific sutures and be-
tween cells at distinct stages of differentiation in a
particular suture (Wang et al. 2005; Holmes et al. 2009;
Heuze et al. 2014; Motch Perrine et al. 2014).
At an early stage of development, osteoprogenitor cell
proliferation in cranial sutures was unchanged (Chen
et al. 2003) or transiently and moderately increased by
Apert- andCrouzon-activating FGFR2mutations (Mansu-
khani et al. 2000, 2005). At a later stage, activating FGFR2
mutations were widely found to cause increased osteo-
blast marker gene expression and accelerated osteoblast
maturation in cranial sutures (Eswarakumar et al. 2004;
Yang et al. 2008; Yin et al. 2008; Holmes et al. 2009;
Yeh et al. 2012; Liu et al. 2013a,b; Morita et al. 2014).
This finding in mice supports the original observation in
humans that Apert and Crouzon FGFR2mutations cause
increased osteoblast maturation and function in postnatal
human suture development (Lomri et al. 1998; Lemonnier
FGF signaling in skeletal development and disease
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et al. 2001b; Tanimoto et al. 2004; Baroni et al. 2005;
Marie 2015). FGFR2 mutations are also associated with
increased osteoblast apoptosis in fused sutures in mice
(Mansukhani et al. 2005; Chen et al. 2014) and humans
(Lemonnier et al. 2001a; Lomri et al. 2001; Kaabeche
et al. 2005); however, this appears to be a secondary event
that occurs subsequent to osteoblast maturation and not
the primary cause of the synostosis (Holmes et al. 2009).
Overall, the current literature indicates that the prema-
ture cranial ossification induced by FGFR2mutations re-
lates to an accelerated maturation of osteoblasts, whereas
the moderate and transient increase in osteoprogenitor
cell recruitment and the late osteoblast apoptosis do not
appear to contribute primarily to the pathogenesis of the
synostosis. The mutations in FGFR2 that causes bent
bone dysplasia (M391R or Y381D) reduce ligand-depen-
dent receptor activation and lead to altered trafficking of
the mutant receptor to the nucleolus. Increased nucleolar
activity of FGFR2 increases ribosomal RNA expression to
promote proliferation and suppresses differentiation of
osteoprogenitor cells (Merrill et al. 2012; Neben et al.
2014).
Besides FGFR1 and FGFR2 mutations, activating
FGFR3 mutations in achondroplasia may also cause par-
tial premature fusion of the coronal sutures, suggesting a
role for FGFR3 activation in membranous ossification
(Twigg et al. 2009; Di Rocco et al. 2014). Indeed, chondro-
cyte-specific activation of Fgfr3 in mice was found to in-
duce premature suture closure and indirectly enhance
osteoblast differentiation through MAPK activation and
BMP signaling (Matsushita et al. 2009b). In long bones,
gain-of-function FGFR3 mutations in chondrocytes, but
not in osteoblasts, caused increased osteoclast recruit-
ment, defective mineralization, and decreased trabecular
bonemass, indicating that overactive FGFR3 signaling in-
directly affects trabecular bone development (Su et al.
2010; Mugniery et al. 2012).
Intracellular pathways involved in craniosynostosis
Genetic and functional studies indicate that the prema-
ture suture fusion induced by FGFR mutations occurs as
a consequence of activation of signaling pathways and
downstream target genes. In several mouse models, Apert
FGFR2(S252W) mutations activate ERK1/2, p38 MAPK,
AKT, β-catenin, and PLCγ in osteogenic cells, which
may contribute to premature cranial ossification (Chen
et al. 2003; Kim et al. 2003; Shukla et al. 2007; Yin et al.
2008; Wang et al. 2010; Suzuki et al. 2012). Interestingly,
reduced dosage of ERF, an inhibitory ETS transcription
factor directly bound by ERK1/2 signaling, was found to
cause craniosynostosis in humans and mice, implying a
role of ERF downstream from ERK signaling in cranial su-
ture ossification (Twigg et al. 2013). In human craniosyn-
ostosis, increased osteoblast gene expression and cranial
osteogenesis induced by Apert FGFR2(S252W) mutation
are related to PLCγ and PKCα activation (Lemonnier
et al. 2001b). The consequence is increased expression of
Runx2, which is associated with premature fusion of cra-
nial sutures inmice and humans (Zhou et al. 2000; Eswar-
akumar et al. 2002; Tanimoto et al. 2004; Baroni et al.
2005; Guenou et al. 2005). In both mice and humans,
FGFR2 levels are decreased in response to the Apert
FGFR2(S252W) mutation as a result of c-CBL-mediated
FGFR2 ubiquitination and degradation (Kaabeche et al.
2004; Holmes et al. 2009). In addition, c-CBL recruitment
by Apert FGFR2(S252W) in human osteoblasts causes
ubiquitination and down-regulation of the Src family
members LYN and FYN (Kaabeche et al. 2004) and α5β1
integrin (Kaabeche et al. 2005), resulting in increased oste-
oblast differentiation and apoptosis, respectively. In-
creased c-CBL recruitment in Apert osteoblasts also
leads to PI3K ubiquitination and degradation, resulting
in attenuation of PI3K signaling and reduced osteoblast
survival (Dufour et al. 2008). Thus, both FGFR-mediated
activation of signaling pathways and down-regulation of
regulatory molecules contribute to the cellular events in
craniosynostosis.
Recent studies indicate that FGFR signaling interacts
with other pathways to induce craniosynostosis. In hu-
man osteoblasts, Apert FGFR2(S252W) mutations cause
increased expression of platelet-derived growth factor re-
ceptor α (PDGFRα) and epidermal growth factor receptor
(EGFR) in osteoblasts via activation of PKCα-mediated
AP-1 transcription, which contributes to premature su-
ture ossification (Miraoui et al. 2010a). Consistent with
these data, transgenic mice conditionally expressing an
constitutively activated PDGFRα in neural crest cells dis-
play activation of PLCγ, resulting in premature fusion at
early postnatal stages (Moenning et al. 2009). FGFR2 acti-
vation caused by Apert FGFR2(S252W) mutations also
leads to increased c-CBL–Sprouty2 interaction and
c-CBL sequestration in human osteoblasts, causing in-
creased EGFR levels and signaling and increased osteo-
blast gene transcription (Miraoui et al. 2010a). Thus,
both transcriptional and post-transcriptionalmechanisms
mediate the aberrant signaling pathways induced by
FGFR2 mutations in cells of the osteoblast lineage.
Therapeutic strategies for FGF-related skeletal disease
Therapeutic strategies in achondroplasia
Skeletal drawfism in hypochondroplasia, achondroplasia,
and thanatophoric dysplasia results from increased
FGFR3 signaling in proliferating and hypertrophic chon-
drocytes (Foldynova-Trantirkova et al. 2012). For achon-
droplasia, in which affected individuals attain adult
heights that arewell below the fifth percentile, pharmaco-
logical therapy promises to offer an alternative to painful
and costly surgical therapies that are currently used to in-
crease height and correct disproportional bone growth.
Several approaches have been proposed to suppress
FGFR3 signaling with the primary goal of enhancing skel-
etal growth (Laederich and Horton 2012). Therapeutic
strategies can target FGF ligands that activate FGFR3,
the activated receptor, signaling pathways that are down-
stream from FGFR3, signaling pathways that modulate
FGFR3 intracellular pathways, or signaling pathways
that are independent of FGFR3 signaling. Tyrosine kinase
Ornitz and Marie
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inhibitors that are selective for FGFRs have thus far not
been effective in vivo because of difficulties in achieving
therapeutic levels of inhibitors in the avascular growth
plate and potential side effects of systemic inhibition of
FGFRs over the long periods for time that will be required
for treatment (Laederich and Horton 2012).
Human growth hormone was evaluated as a therapy;
however, no long-term benefits were observed (Kanazawa
et al. 2003; Horton et al. 2007). An antihistamine drug,
meclozine dihydrochloride, has been shown to inhibit
FGFR3 signaling in chondrocytes by suppressing ERK1/2
phosphorylation. Meclozine functioned to enhance bone
growth in explant culture and increase bone growth in
wild-type and achondroplasia mice (Matsushita et al.
2013, 2015). Inhibition of ligands that activate FGFR3
can be achieved through expression of a soluble extracel-
lular domain of FGFR3 (sFGFR3) that can compete with
endogenous FGFR3 by binding FGF ligands such as
FGF9 and FGF18 that functionally regulate the growth
plate (Liu et al. 2002, 2007; Ohbayashi et al. 2002; Hung
et al. 2007; Garcia et al. 2013). Subcutaneous injections
of recombinant sFGFR3 in a mouse model for achondro-
plasia was found to decrease mortality and improve skel-
etal growth (Garcia et al. 2013). Inhibitory antibodies
that specifically target the FGFR3 extracellular domain
have been developed as potential cancer therapeutics
but have not been evaluated for treatment of achondropla-
sia (Martinez-Torrecuadrada et al. 2005; Hadari and
Schlessinger 2009; Qing et al. 2009). A recent drug screen
of induced pluripotent stem cell-derived chondrocytes
from patients with achondroplasia and thanatophoric dys-
plasia identified statin drugs as effective in improving
chondrogenic differentiation in vitro and improving the
phenotype (limb and body length) of achondroplasia
mice in vivo (Yamashita et al. 2014).
The most promising therapy thus far for treatment of
achondroplasia is the use of a stabilized form of CNP
called BMN-111 (Lorget et al. 2012; Wendt et al. 2015).
BMN-111 is currently undergoing clinical trials for the
treatment of achondroplasia (https://clinicaltrials.gov/
ct2/show/NCT02055157). Mice or humans that overex-
press CNP or activate natriuretic peptide receptor 2
(Npr2; guanylyl cyclase B) have a skeletal overgrowth phe-
notype (Fig. 2; Yasoda et al. 2004; Bocciardi et al. 2007;
Hannema et al. 2013; Miura et al. 2014), while mice that
lack CNP (Nppc−/−) or humans with heterozygous muta-
tions in NPR2 exhibit skeletal dwarfism (Tsuji and
Kunieda 2005; Nakao et al. 2015).
CNP signals through NPR2 in chondrocytes and inhib-
its the MAPK signaling pathway at the level of RAF1 (Fig.
2). Several studies suggest amechanism inwhichCNP-in-
duced cGMP activates cyclic GMP-dependent protein ki-
nase II (cGKII; encoded by PRKG2) and p38 (MAPK14),
which functionally antagonizes RAF1 activation of MEK
(MAP2K1), which is a critical pathway regulating chon-
drocyte hypertrophy (Murakami et al. 2004; Ozasa et al.
2005; Agoston et al. 2007; Hutchison 2012; Peake et al.
2014). Interestingly, FGFR3–MAPK signalingmay also in-
hibit cGMP production in chondrocytes (Ozasa et al.
2005). Thus, signaling by FGF ligands (FGF9 and FGF18)
through FGFR3 functionally antagonizes CNP signaling
through NPR2 to regulate the rate of chondrocyte hyper-
trophy. Consistent with feedback regulation of the FGF
and CNP pathways in chondrocytes, patients with acti-
vatingmutations in FGFR3 have increased circulating lev-
els of CNP (Olney et al. 2015).
Therapeutic strategies in craniosynostosis
The identification of the aberrant signals induced by
FGFR mutations provided clues for potential therapeutic
nonsurgical interventions in craniosynostosis (Wilkie
2007; Melville et al. 2010). In vitro, overactivated FGFR2
signaling by Apert and Crouzon mutations can be attenu-
ated by specific glycosaminoglycans (McDowell et al.
2006), FGFR or tyrosine kinase inhibitors (Perlyn et al.
2006), or a soluble mutant form of FGFR2 that exerts a
dominant-negative effect on FGFR2 (Tanimoto et al.
2004). In vivo, selective uncoupling of the docking protein
FRS2α and the Crouzon-like activated FGFR2c mutant
was found to attenuate FGFR signaling and prevent pre-
mature suture fusion in mice (Eswarakumar et al. 2006).
In mice, treatments with a shRNA targeting the Apert
FGFR2(S252W) mutation or the use of a ERK1/2 MAPK
inhibitor (Shukla et al. 2007) or a soluble mutant form of
FGFR2 (Morita et al. 2014; Yokota et al. 2014) were also
found to prevent craniosynostosis. The recent finding
that FGFR signaling interacts with PDGFRα signaling to
induce premature suture fusion in mice and humans
may offer alternative therapeutic strategies to indirectly
attenuate signals induced by activating FGFR mutations
(Moenning et al. 2009; Miraoui et al. 2010a). These recent
studiesmay thus provide promising therapeutic strategies
to efficiently reduce the aberrant FGFR signaling induced
by Fgfr2mutations in craniosynostosis.
FGF and bone regeneration
Fgf and Fgfr expression are regulated during fracture heal-
ing (Schmid et al. 2009), and there are accumulating data
indicating that FGF/FGFR signaling plays active roles dur-
ing the fracture repair process (Du et al. 2012; Fei et al.
2013). These studies led to the wide use of FGF2 as a ther-
apeutic agent for promoting bone regeneration in animal
models (Fei et al. 2013). Typically, the local implantation
of FGF2 impregnated in a gelatin hydrogel or a molecular
scaffold or the injection of chemically controlled FGF2-se-
creting cells was found to promote bone healing in cranial
or long bone defects (Chen et al. 2004; Komaki et al. 2006;
Kodama et al. 2009; Kawaguchi et al. 2010; Kwan et al.
2011). However, the effects on bone healing are dependent
on the dose used, the time of application, and the duration
of FGF treatment (Du et al. 2012; Fei et al. 2013). The an-
abolic effect of locally injected FGF2 results mainly from
increased expansion of the pool of osteoblast precursor
cells, resulting in their differentiation into osteoblasts
(Nakamura et al. 1998; Nakajima et al. 2007). In addition,
FGF2 may also increase angiogenesis at the site of injury.
A close spatial and temporal relationship exists between
FGF signaling in skeletal development and disease
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angiogenesis and osteogenesis during bone repair and en-
dochondral bone formation, and the connection between
the two processes is essential for bone formation (Dirckx
et al. 2013; Saran et al. 2014). Recent genetic studies indi-
cate that FGF/FGFR signaling plays an essential role in
both processes. It was shown that FGF9−/+ mice display
reduced repair of cortical bone defects resulting from de-
creased osteoblast proliferation and differentiation associ-
ated with impaired neovascularization and reduced Vegf
expression. This phenotype was rescued by exogenous
FGF9, indicating that endogenous FGF9 is important for
cortical bone repair in part through regulatingVegf expres-
sion (Behr et al. 2010). In addition to promoting angiogen-
esis, VEGF controls bone formation by stimulating the
differentiation of mesenchymal stem cells to osteoblasts
(Liu and Olsen 2014). Accordingly, VEGF alone has a po-
tent bone repair potential by promoting angiogenesis
and osteogenesis in vivo (Behr et al. 2012). Since FGF2 pro-
motes Vegf expression in osteoblasts (Takai et al. 2007),
these two factors may promote bone repair through acti-
vation of both angiogenesis and osteogenesis. Fgf18−/+
mice also showed reduced cortical bone defect healing ca-
pacity but due to decreased osteoblast differentiationwith
normal angiogenesis, showing that FGF18 is required for
osteogenesis but not angiogenesis during bone repair
(Behr et al. 2011). In a mouse model of skeletal prosthesis
insertion, a local injection of FGF18 resulted in increased
peri-implant bone formation in both Fgfr3+/+ and Fgfr3−/−
mice, indicating that FGF18 can promote bone repair in-
dependently of FGFR3 (Carli et al. 2012), presumably
through activation of FGFR1 and/or FGFR2. In line with
this concept, it was recently found that DJ-1 (PARK7),
an angiogenic protein, stimulates both osteoblast differen-
tiation and angiogenesis via FGFR1 activation, resulting
in enhanced long bone fracture repair in rats, further high-
lighting the importance of FGFR1 signaling in fracture re-
pair (Kim et al. 2012). Overall, these studies uncover novel
roles for FGF/FGFR signaling in bone repair through acti-
vation of both angiogenesis and osteogenesis, supporting
the concept that FGFs may have therapeutic potential to
stimulate bone regeneration.
Conclusion
During the past decade, significant advances have been
made in our understanding of the role of FGF/FGFR sig-
naling in skeletal development, bone formation, and
bone diseases. Specifically, the analysis of genetic models
in mice led to a better understanding of the complex role
of FGF/FGFR signaling in endochondral and intramem-
branous ossification and bone repair. Also, the analysis
of the skeletal phenotype induced by FGFR mutations in
various mouse models and human skeletal dysplasias
has improved our knowledge of the pathogenesis of chon-
drodysplasias and craniosynostosis. Finally, genetic and
functional studies led to the identification of aberrant sig-
naling mechanisms involved in skeletal diseases associat-
ed with FGFR mutations. This knowledge validated the
concept thatmodulating FGFR signaling and downstream
signaling pathways can prevent skeletal dysplasias in-
duced by Fgfrmutations in mice, and this important con-
cept may lead to novel therapeutic approaches in human
skeletal dysplasias. In the future, further studies are need-
ed to delineate the stage-specific role of FGF/FGFR signal-
ing in cells of the chondrocyte and osteoblast lineage
in vivo and characterize FGF interactionswith other effec-
tors during normal and aberrant chondrogenesis and
osteogenesis. It is expected that a more complete under-
standing of the role FGF/FGFR signaling in prenatal and
postnatal skeletal development will translate into novel
therapeutic approaches for human skeletal dysplasias
and improved skeletal repair.
Acknowledgments
We thank all team members who contributed to the work re-
viewed here. We apologize to the investigators whose work
could not be cited due to space limitations. This work was sup-
ported by National Institutes of Health grant HD049808 (to
D.M.O.), the Institut National de la Recherche Médicale, Uni-
versity Paris Diderot Sorbonne Paris Cité, the DIM Stem Pôle
Ile de France, the French Minister of Research, and the Asssoci-
ation Prévention et Traitement des Décalcifications (Paris,
France) (to P.J.M.).
References
Abad V, Meyers JL, Weise M, Gafni RI, Barnes KM, Nilsson O,
Bacher JD, Baron J. 2002. The role of the resting zone in growth
plate chondrogenesis. Endocrinology 143: 1851–1857.
Agas D, Marchetti L, Menghi G, Materazzi S, Materazzi G, Ca-
pacchietti M, Hurley MM, Sabbieti MG. 2008. Anti-apoptotic
Bcl-2 enhancing requires FGF-2/FGF receptor 1 binding in
mouse osteoblasts. J Cell Physiol 214: 145–152.
Agas D, Sabbieti MG, Marchetti L, Xiao L, Hurley MM. 2013.
FGF-2 enhances Runx-2/Smads nuclear localization in BMP-
2 canonical signaling in osteoblasts. J Cell Physiol 228:
2149–2158.
Agoston H, Khan S, James CG, Gillespie JR, Serra R, Stanton LA,
Beier F. 2007. C-type natriuretic peptide regulates endochon-
dral bone growth through p38MAP kinase-dependent and -in-
dependent pathways. BMC Dev Biol 7: 18.
Aikawa T, Segre GV, Lee K. 2001. Fibroblast growth factor inhib-
its chondrocytic growth through induction of p21 and subse-
quent inactivation of cyclin E–Cdk2. J Biol Chem 276:
29347–29352.
Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crom-
brugghe B. 2002. The transcription factor Sox9 has essential
roles in successive steps of the chondrocyte differentiation
pathway and is required for expression of Sox5 and Sox6.
Genes Dev 16: 2813–2828.
Ambrosetti D, HolmesG,Mansukhani A, Basilico C. 2008. Fibro-
blast growth factor signaling uses multiple mechanisms to in-
hibit Wnt-induced transcription in osteoblasts.Mol Cell Biol
28: 4759–4771.
Barnard JC, Williams AJ, Rabier B, Chassande O, Samarut J,
Cheng SY, Bassett JH, Williams GR. 2005. Thyroid hormones
regulate fibroblast growth factor receptor signaling during
chondrogenesis. Endocrinology 146: 5568–5580.
Baroni T, Carinci P, Lilli C, Bellucci C, Aisa MC, Scapoli L, Voli-
nia S, Carinci F, Pezzetti F, CalvittiM, et al. 2005. P253R fibro-
blast growth factor receptor-2 mutation induces RUNX2
Ornitz and Marie
1476 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
transcript variants and calvarial osteoblast differentiation. J
Cell Physiol 202: 524–535.
Beever JE, SmitMA,Meyers SN, Hadfield TS, Bottema C, Albret-
sen J, Cockett NE. 2006. A single-base change in the tyrosine
kinase II domain of ovine FGFR3 causes hereditary chondro-
dysplasia in sheep. Anim Genet 37: 66–71.
Behr B, Leucht P, Longaker MT, Quarto N. 2010. Fgf-9 is required
for angiogenesis and osteogenesis in long bone repair. Proc
Natl Acad Sci 107: 11853–11858.
Behr B, Sorkin M, Manu A, Lehnhardt M, Longaker MT, Quarto
N. 2011. Fgf-18 is required for osteogenesis but not angiogen-
esis during long bone repair. Tissue Eng Part A 17: 2061–2069.
Behr B, Sorkin M, Lehnhardt M, Renda A, Longaker MT, Quarto
N. 2012. A comparative analysis of the osteogenic effects of
BMP-2, FGF-2, and VEGFA in a calvarial defect model. Tissue
Eng Part A 18: 1079–1086.
BellusGA,McIntosh I, Smith EA,AylsworthAS, Kaitila I, Horton
WA,GreenhawGA,Hecht JT, FrancomanoCA. 1995. A recur-
rent mutation in the tyrosine kinase domain of fibroblast
growth factor receptor 3 causes hypochondroplasia. Nat Ge-
net 10: 357–359.
Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko O,
Jabs EW, Curry CJ, Wilcox WR, Lachman RS, et al. 1999.
Severe achondroplasiawith developmental delay and acantho-
sis nigricans (SADDAN): phenotypic analysis of a new skele-
tal dysplasia caused by a Lys650Met mutation in fibroblast
growth factor receptor 3. Am J Med Genet 85: 53–65.
BellusGA, Spector EB, Speiser PW,Weaver CA, Garber AT, Bryke
CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, et al.
2000. Distinct missense mutations of the FGFR3 Lys650 co-
don modulate receptor kinase activation and the severity of
the skeletal dysplasia phenotype. Am J Hum Genet 67:
1411–1421.
BelovAA,MohammadiM. 2013.Molecularmechanisms of fibro-
blast growth factor signaling in physiology and pathology.
Cold Spring Harb Perspect Biol 5: 1–24.
Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. 1999.
Sox9 is required for cartilage formation.Nat Genet 22: 85–89.
BlickC, RamachandranA,Wigfield S,McCormickR, JubbA, Buf-
fa FM, Turley H, Knowles MA, Cranston D, Catto J, et al.
2013. Hypoxia regulates FGFR3 expression via HIF-1α and
miR-100 and contributes to cell survival in non-muscle inva-
sive bladder cancer. Br J Cancer 109: 50–59.
Bocciardi R, Giorda R, Buttgereit J, Gimelli S, Divizia MT, Beri S,
Garofalo S, Tavella S, Lerone M, Zuffardi O, et al. 2007. Over-
expression of the C-type natriuretic peptide (CNP) is associat-
ed with overgrowth and bone anomalies in an individual with
balanced t(2;7) translocation. Hum Mutat 28: 724–731.
Bonaventure J, Rousseau F, Legeai-Mallet L, Le Merrer M, Mun-
nich A, Maroteaux P. 1996. Common mutations in the fibro-
blast growth factor receptor 3 (FGFR 3) gene account for
achondroplasia, hypochondroplasia, and thanatophoric dwarf-
ism. Am J Med Genet 63: 148–154.
Bosetti M, Leigheb M, Brooks RA, Boccafoschi F, Cannas MF.
2010. Regulation of osteoblast and osteoclast functions by
FGF-6. J Cell Physiol 225: 466–471.
Britto JA, Evans RD, Hayward RD, Jones BM. 2001. From geno-
type to phenotype: the differential expression of FGF, FGFR,
and TGFβ genes characterizes human cranioskeletal develop-
ment and reflects clinical presentation in FGFR syndromes.
Plast Reconstr Surg 108: 2026–2039.
Brodie SG,KitohH, LachmanRS,Nolasco LM,Mekikian PB,Wil-
cox WR. 1999. Platyspondylic lethal skeletal dysplasia, San
Diego type, is caused by FGFR3 mutations. Am J Med Genet
84: 476–480.
Browaeys-Poly E, Blanquart C, Perdereau D, Antoine AF, Goe-
naga D, Luzy JP, Chen H, Garbay C, Issad T, Cailliau K,
et al. 2010. Grb14 inhibits FGF receptor signaling through
the regulation of PLCγ recruitment and activation. FEBS
Lett 584: 4383–4388.
Buchtova M, Oralova V, Aklian A, Masek J, Vesela I, Ouyang Z,
Obadalova T, Konecna Z, Spoustova T, Pospisilova T, et al.
2015. Fibroblast growth factor and canonical WNT/β-catenin
signaling cooperate in suppression of chondrocyte differentia-
tion in experimental models of FGFR signaling in cartilage.
Biochim Biophys Acta 1852: 839–850.
Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Cha-
bert C, Boschert U, Arkinstall S. 1998. Catalytic activation
of the phosphataseMKP-3 by ERK2mitogen-activated protein
kinase. Science 280: 1262–1265.
Carli A, Gao C, Khayyat-Kholghi M, Li A, Wang H, Ladel C, Har-
vey EJ, Henderson JE. 2012. FGF18 augments osseointegration
of intra-medullary implants in osteopenic FGFR3−/−mice.Eur
Cell Mater 24: 107–116.
Chen L, Deng CX. 2005. Roles of FGF signaling in skeletal devel-
opment and human genetic diseases. Front Biosci 10:
1961–1976.
Chen Y, Gridley T. 2013. Compensatory regulation of the Snai1
and Snai2 genes during chondrogenesis. J Bone Miner Res
28: 1412–1421.
Chen L, Li C, QiaoW, Xu X, Deng C. 2001. A Ser(365)→Cysmu-
tation of fibroblast growth factor receptor 3 in mouse downre-
gulates Ihh/PTHrP signals and causes severe achondroplasia.
Hum Mol Genet 10: 457–465.
Chen L, Li D, Li C, Engel A,DengCX. 2003. A Ser252Trp [correct-
ed] substitution in mouse fibroblast growth factor receptor 2
(Fgfr2) results in craniosynostosis. Bone 33: 169–178.
ChenWJ, Jingushi S, Aoyama I, Anzai J, HirataG, TamuraM, Iwa-
moto Y. 2004. Effects of FGF-2 on metaphyseal fracture repair
in rabbit tibiae. J Bone Miner Metab 22: 303–309.
Chen P, Zhang L, Weng T, Zhang S, Sun S, ChangM, Li Y, Zhang
B, Zhang L. 2014. A Ser252Trp mutation in fibroblast growth
factor receptor 2 (FGFR2) mimicking human Apert syndrome
reveals an essential role for FGF signaling in the regulation of
endochondral bone formation. PLoS One 9: e87311.
ChikazuD, Hakeda Y, Ogata N, Nemoto K, Itabashi A, Takato T,
Kumegawa M, Nakamura K, Kawaguchi H. 2000. Fibroblast
growth factor (FGF)-2 directly stimulates mature osteoclast
function through activation of FGF receptor 1 and p42/p44
MAP kinase. J Biol Chem 275: 31444–31450.
Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T,
Takato T, Nakamura K, Kawaguchi H. 2001. Regulation of os-
teoclast differentiation by fibroblast growth factor 2: stimula-
tion of receptor activator of nuclear factor κB ligand/osteoclast
differentiation factor expression in osteoblasts and inhibition
of macrophage colony-stimulating factor function in osteo-
clast precursors. J Bone Miner Res 16: 2074–2081.
Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, Furuichi T,
Komori T, Nam SH, KimYJ, Ryoo HM. 2005. Runx2 regulates
FGF2-induced Bmp2 expression during cranial bone develop-
ment. Dev Dyn 233: 115–121.
Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS. 2008. Fi-
broblast growth factor-2 and -4 promote the proliferation of
bone marrow mesenchymal stem cells by the activation of
the PI3K–Akt and ERK1/2 signaling pathways. Stem Cells
Dev 17: 725–736.
CobrinikD, LeeMH,HannonG,MulliganG, Bronson RT, Dyson
N, Harlow E, Beach D, Weinberg RA, Jacks T. 1996. Shared
role of the pRB-related p130 and p107 proteins in limb devel-
opment. Genes Dev 10: 1633–1644.
FGF signaling in skeletal development and disease
GENES & DEVELOPMENT 1477
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM.
1996. Skeletal overgrowth and deafness in mice lacking fibro-
blast growth factor receptor 3. Nat Genet 12: 390–397.
Coumoul X, Shukla V, Li C, Wang RH, Deng CX. 2005. Condi-
tional knockdown of Fgfr2 in mice using Cre-LoxP induced
RNA interference. Nucleic Acids Res 33: e102.
Coutu DL, Francois M, Galipeau J. 2011. Inhibition of cellular
senescence by developmentally regulated FGF receptors in
mesenchymal stem cells. Blood 117: 6801–6812.
Cowan CM,Quarto N,Warren SM, SalimA, LongakerMT. 2003.
Age-related changes in the biomolecular mechanisms of cal-
varial osteoblast biology affect fibroblast growth factor-2 sig-
naling and osteogenesis. J Biol Chem 278: 32005–32013.
Dailey L, Laplantine E, Priore R, Basilico C. 2003. A network of
transcriptional and signaling events is activated by FGF to in-
duce chondrocyte growth arrest and differentiation. J Cell Biol
161: 1053–1066.
Dailey L, Ambrosetti D, Mansukhani A, Basilico C. 2005. Mech-
anisms underlying differential responses to FGF signaling.Cy-
tokine Growth Factor Rev 16: 233–247.
Dakouane Giudicelli M, Serazin V, Le Sciellour CR, Albert M,
Selva J, Giudicelli Y. 2008. Increased achondroplasiamutation
frequency with advanced age and evidence for G1138Amosa-
icism in human testis biopsies. Fertil Steril 89: 1651–1656.
Debiais F, Hott M, Graulet AM, Marie PJ. 1998. The effects of fi-
broblast growth factor-2 on human neonatal calvaria osteo-
blastic cells are differentiation stage specific. J Bone Miner
Res 13: 645–654.
de Frutos CA, Vega S, Manzanares M, Flores JM, Huertas H, Mar-
tinez-FriasML, NietoMA. 2007. Snail1 is a transcriptional ef-
fector of FGFR3 signaling during chondrogenesis and
achondroplasias. Dev Cell 13: 872–883.
Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, Le Merrer M,
Munnich A, Vekemans M, Bonaventure J. 1998. Spatio–tem-
poral expression of FGFR 1, 2 and 3 genes during human em-
bryo–fetal ossification.Mech Dev 77: 19–30.
Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. 1996. Fibro-
blast growth factor receptor 3 is a negative regulator of bone
growth. Cell 84: 911–921.
Di Maggio N, Mehrkens A, Papadimitropoulos A, Schaeren S,
Heberer M, Banfi A, Martin I. 2012. Fibroblast growth factor-
2 maintains a niche-dependent population of self-renewing
highly potent non-adherent mesenchymal progenitors
through FGFR2c. Stem Cells 30: 1455–1464.
Dirckx N, Van Hul M, Maes C. 2013. Osteoblast recruitment to
sites of bone formation in skeletal development, homeostasis,
and regeneration. Birth Defects Res C Embryo Today 99:
170–191.
Di Rocco F, Biosse Duplan M, Heuze Y, Kaci N, Komla-Ebri D,
Munnich A, Mugniery E, Benoist-Lasselin C, Legeai-Mallet
L. 2014. FGFR3mutation causes abnormal membranous ossi-
fication in achondroplasia. Hum Mol Genet 23: 2914–2925.
Du X, Xie Y, Xian CJ, Chen L. 2012. Role of FGFs/FGFRs in skel-
etal development and bone regeneration. J Cell Physiol 227:
3731–3743.
DufourC,GuenouH, KaabecheK, BouvardD, Sanjay A,Marie PJ.
2008. FGFR2–Cbl interaction in lipid rafts triggers attenua-
tion of PI3K/Akt signaling and osteoblast survival. Bone 42:
1032–1039.
Dy P,WangW, Bhattaram P,Wang Q,Wang L, Ballock RT, Lefeb-
vre V. 2012. Sox9 directs hypertrophic maturation and blocks
osteoblast differentiation of growth plate chondrocytes. Dev
Cell 22: 597–609.
Eswarakumar VP, Schlessinger J. 2007. Skeletal overgrowth is
mediated by deficiency in a specific isoform of fibroblast
growth factor receptor 3. Proc Natl Acad Sci 104: 3937–3942.
Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou
I, Morriss-Kay GM, Lonai P. 2002. The IIIc alternative of
Fgfr2 is a positive regulator of bone formation. Development
129: 3783–3793.
Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM,
Lonai P. 2004. A gain-of-function mutation of Fgfr2c demon-
strates the roles of this receptor variant in osteogenesis. Proc
Natl Acad Sci 101: 12555–12560.
Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling
by fibroblast growth factor receptors.CytokineGrowth Factor
Rev 16: 139–149.
Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tome F, Booth CJ,
AdamsDJ, Lax I, Schlessinger J. 2006. Attenuation of signaling
pathways stimulated by pathologically activated FGF-recep-
tor 2 mutants prevents craniosynostosis. Proc Natl Acad Sci
103: 18603–18608.
Fakhry A, Ratisoontorn C, Vedhachalam C, Salhab I, Koyama E,
Leboy P, Pacifici M, Kirschner RE, Nah HD. 2005. Effects of
FGF-2/-9 in calvarial bone cell cultures: differentiation
stage-dependent mitogenic effect, inverse regulation of
BMP-2 and noggin, and enhancement of osteogenic potential.
Bone 36: 254–266.
Fei Y, Xiao L, Doetschman T, Coffin DJ, HurleyMM. 2011. Fibro-
blast growth factor 2 stimulation of osteoblast differentiation
and bone formation ismediated bymodulation of theWnt sig-
naling pathway. J Biol Chem 286: 40575–40583.
Fei Y, Gronowicz G, Hurley MM. 2013. Fibroblast growth factor-
2, bone homeostasis and fracture repair. Curr Pharm Des 19:
3354–3363.
Feng JQ, Clinkenbeard EL, Yuan B, White KE, DreznerMK. 2013.
Osteocyte regulation of phosphate homeostasis and bonemin-
eralization underlies the pathophysiology of the heritable dis-
orders of rickets and osteomalacia. Bone 54: 213–221.
Foldynova-Trantirkova S, Wilcox WR, Krejci P. 2012. Sixteen
years and counting: the current understanding of fibroblast
growth factor receptor 3 (FGFR3) signaling in skeletal dyspla-
sias. Hum Mutat 33: 29–41.
Ford-Hutchinson AF, Ali Z, Lines SE, Hallgrimsson B, Boyd SK,
Jirik FR. 2007. Inactivation of Pten in osteo-chondroprogeni-
tor cells leads to epiphyseal growth plate abnormalities and
skeletal overgrowth. J Bone Miner Res 22: 1245–1259.
Fromigue O, Modrowski D, Marie PJ. 2004. Growth factors and
bone formation in osteoporosis: roles for fibroblast growth fac-
tor and transforming growth factor β. Curr Pharm Des 10:
2593–2603.
Fromigue O, Modrowski D, Marie PJ. 2005. Apoptosis in mem-
branous bone formation: role of fibroblast growth factor and
bone morphogenetic protein signaling. Crit Rev Eukaryot
Gene Expr 15: 75–92.
Furdui CM, Lew ED, Schlessinger J, Anderson KS. 2006. Auto-
phosphorylation of FGFR1 kinase is mediated by a sequential
and precisely ordered reaction.Mol Cell 21: 711–717.
Garcia S, Dirat B, Tognacci T, Rochet N,Mouska X, Bonnafous S,
Patouraux S, Tran A, Gual P, Le Marchand-Brustel Y, et al.
2013. Postnatal soluble FGFR3 therapy rescues achondropla-
sia symptoms and restores bone growth in mice. Sci Transl
Med 5: 203ra124.
Goetz R, Mohammadi M. 2013. Exploring mechanisms of FGF
signalling through the lens of structural biology. Nat Rev
Mol Cell Biol 14: 166–180.
Gonzalez AM, Hill DJ, Logan A, Maher PA, Baird A. 1996. Distri-
bution of fibroblast growth factor (FGF)-2 and FGF receptor-1
Ornitz and Marie
1478 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
messenger RNA expression and protein presence in the mid-
trimester human fetus. Pediatr Res 39: 375–385.
Goriely A, Wilkie AO. 2012. Paternal age effect mutations and
selfish spermatogonial selection: causes and consequences
for human disease. Am J Hum Genet 90: 175–200.
Goriely A, McVean GA, Rojmyr M, Ingemarsson B, Wilkie AO.
2003. Evidence for selective advantage of pathogenic FGFR2
mutations in the male germ line. Science 301: 643–646.
Goriely A, McVean GA, van Pelt AM, O’Rourke AW,Wall SA, de
Rooij DG,Wilkie AO. 2005. Gain-of-function amino acid sub-
stitutions drive positive selection of FGFR2 mutations in hu-
man spermatogonia. Proc Natl Acad Sci 102: 6051–6056.
Guenou H, Kaabeche K, Mee SL, Marie PJ. 2005. A role for fibro-
blast growth factor receptor-2 in the altered osteoblast pheno-
type induced by Twist haploinsufficiency in the Saethre-
Chotzen syndrome. Hum Mol Genet 14: 1429–1439.
Hadari Y, Schlessinger J. 2009. FGFR3-targeted mAb therapy for
bladder cancer and multiple myeloma. J Clin Invest 119:
1077–1079.
Hajihosseini MK. 2008. Fibroblast growth factor signaling in cra-
nial suture development and pathogenesis. FrontOral Biol 12:
160–177.
Hall BK, Miyake T. 2000. All for one and one for all: condensa-
tions and the initiation of skeletal development. Bioessays
22: 138–147.
HamadaT, SudaN, KurodaT. 1999. Immunohistochemical local-
ization of fibroblast growth factor receptors in the rat mandib-
ular condylar cartilage and tibial cartilage. J Bone Miner
Metab 17: 274–282.
Hamidouche Z, Fromigue O, Nuber U, Vaudin P, Pages JC, Ebert
R, Jakob F, Miraoui H, Marie PJ. 2010. Autocrine fibroblast
growth factor 18 mediates dexamethasone-induced osteogen-
ic differentiation of murine mesenchymal stem cells. J Cell
Physiol 224: 509–515.
Han X, Xiao Z, Quarles LD. 2015. Membrane and integrative nu-
clear fibroblastic growth factor receptor (FGFR) regulation of
FGF-23. J Biol Chem 290: 10447–10459.
Hanafusa H, Torii S, Yasunaga T, Nishida E. 2002. Sprouty1 and
Sprouty2 provide a control mechanism for the Ras/MAPK sig-
nalling pathway. Nat Cell Biol 4: 850–858.
Hannema SE, van Duyvenvoorde HA, Premsler T, Yang RB,
Mueller TD, Gassner B, Oberwinkler H, Roelfsema F, Santen
GW, Prickett T, et al. 2013. An activating mutation in the ki-
nase homology domain of the natriuretic peptide receptor-2
causes extremely tall stature without skeletal deformities. J
Clin Endocrinol Metab 98: E1988–E1998.
HaradaM,MurakamiH, OkawaA, OkimotoN,Hiraoka S, Naka-
hara T, Akasaka R, Shiraishi Y, Futatsugi N, Mizutani-Koseki
Y, et al. 2009. FGF9monomer/dimer equilibrium regulates ex-
tracellular matrix affinity and tissue diffusion. Nat Genet 41:
289–298.
Hatch NE, Hudson M, Seto ML, Cunningham ML, Bothwell M.
2006. Intracellular retention, degradation, and signaling of gly-
cosylation-deficient FGFR2 and craniosynostosis syndrome-
associated FGFR2C278F. J Biol Chem 281: 27292–27305.
Haupt LM, Murali S, Mun FK, Teplyuk N, Mei LF, Stein GS, van
Wijnen AJ, Nurcombe V, Cool SM. 2009. The heparan sulfate
proteoglycan (HSPG) glypican-3 mediates commitment of
MC3T3-E1 cells toward osteogenesis. J Cell Physiol 220:
780–791.
Havens BA, Velonis D, Kronenberg MS, Lichtler AC, Oliver B,
Mina M. 2008. Roles of FGFR3 during morphogenesis of
Meckel’s cartilage and mandibular bones. Dev Biol 316:
336–349.
Heuze Y, Singh N, Basilico C, Jabs EW, Holmes G, Richtsmeier
JT. 2014. Morphological comparison of the craniofacial phe-
notypes of mouse models expressing the Apert FGFR2
S252W mutation in neural crest- or mesoderm-derived tis-
sues. Bone 63: 101–109.
Hinoi E, Bialek P, Chen YT, RachedMT, Groner Y, Behringer RR,
Ornitz DM, Karsenty G. 2006. Runx2 inhibits chondrocyte
proliferation and hypertrophy through its expression in the
perichondrium. Genes Dev 20: 2937–2942.
HolmesG, RothschildG, RoyUB,DengCX,MansukhaniA, Basi-
lico C. 2009. Early onset of craniosynostosis in an Apert
mouse model reveals critical features of this pathology. Dev
Biol 328: 273–284.
Homer-Bouthiette C, Doetschman T, Xiao L, Hurley MM. 2014.
Knockout of nuclear high molecular weight FGF2 isoforms in
mice modulates bone and phosphate homeostasis. J Biol
Chem 289: 36303–36314.
Horton WA, Hall JG, Hecht JT. 2007. Achondroplasia. Lancet
370: 162–172.
House SL, Branch K, Newman G, Doetschman T, Schultz Jel J.
2005. Cardioprotection induced by cardiac-specific overex-
pression of fibroblast growth factor-2 is mediated by the
MAPK cascade. Am J Physiol Heart Circ Physiol 289:
H2167–H2175.
Hung IH, Yu K, Lavine KJ, Ornitz DM. 2007. FGF9 regulates early
hypertrophic chondrocyte differentiation and skeletal vascu-
larization in the developing stylopod. Dev Biol 307: 300–313.
Hunziker EB, Schenk RK. 1989. Physiological mechanisms
adopted by chondrocytes in regulating longitudinal bone
growth in rats. J Physiol 414: 55–71.
Hunziker EB, Schenk RK, Cruz-Orive LM. 1987. Quantitation of
chondrocyte performance in growth-plate cartilage during
longitudinal bone growth. J Bone Joint Surg Am 69: 162–173.
Hurley MM, Tetradis S, Huang YF, Hock J, Kream BE, Raisz LG,
SabbietiMG. 1999. Parathyroid hormone regulates the expres-
sion of fibroblast growth factor-2mRNAand fibroblast growth
factor receptor mRNA in osteoblastic cells. J Bone Miner Res
14: 776–783.
Hutchison MR. 2012. BDNF alters ERK/p38 MAPK activity ra-
tios to promote differentiation in growth plate chondrocytes.
Mol Endocrinol 26: 1406–1416.
Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM,
Mohammadi M. 2001. Structural basis for fibroblast growth
factor receptor 2 activation in Apert syndrome. Proc Natl
Acad Sci 5: 5.
Ignelzi MA Jr, Wang W, Young AT. 2003. Fibroblast growth fac-
tors lead to increased Msx2 expression and fusion in calvarial
sutures. J Bone Miner Res 18: 751–759.
IkegamiD, AkiyamaH, Suzuki A,Nakamura T,NakanoT, Yosh-
ikawa H, Tsumaki N. 2011. Sox9 sustains chondrocyte sur-
vival and hypertrophy in part through Pik3ca–Akt pathways.
Development 138: 1507–1519.
Iwata T, Chen L, Li C, Ovchinnikov DA, Behringer RR, Franco-
mano CA, Deng CX. 2000. A neonatal lethal mutation in
FGFR3 uncouples proliferation and differentiation of growth
plate chondrocytes in embryos. Hum Mol Genet 9:
1603–1613.
IwataT, Li CL,DengCX, FrancomanoCA. 2001.Highly activated
Fgfr3 with the K644Mmutation causes prolonged survival in
severe dwarf mice. Hum Mol Genet 10: 1255–1264.
Jackson RA, Murali S, van Wijnen AJ, Stein GS, Nurcombe V,
Cool SM. 2007.Heparan sulfate regulates the anabolic activity
ofMC3T3-E1 preosteoblast cells by induction of Runx2. J Cell
Physiol 210: 38–50.
FGF signaling in skeletal development and disease
GENES & DEVELOPMENT 1479
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Jacob AL, Smith C, Partanen J, Ornitz DM. 2006. Fibroblast
growth factor receptor 1 signaling in the osteo-chondrogenic
cell lineage regulates sequential steps of osteoblast matura-
tion. Dev Biol 296: 315–328.
Jeon E, Yun YR, Kang W, Lee S, Koh YH, Kim HW, Suh CK, Jang
JH. 2012. Investigating the role of FGF18 in the cultivation
and osteogenic differentiation of mesenchymal stem cells.
PLoS One 7: e43982.
Johnson D, Wilkie AO. 2011. Craniosynostosis. Eur J HumGenet
19: 369–376.
Kaabeche K, Lemonnier J, LeMee S, Caverzasio J, Marie PJ. 2004.
Cbl-mediated degradation of Lyn and Fyn induced by constitu-
tive fibroblast growth factor receptor-2 activation supports os-
teoblast differentiation. J Biol Chem 279: 36259–36267.
Kaabeche K, Guenou H, Bouvard D, Didelot N, Listrat A, Marie
PJ. 2005. Cbl-mediated ubiquitination of α5 integrin subunit
mediates fibronectin-dependent osteoblast detachment and
apoptosis induced by FGFR2 activation. J Cell Sci 118:
1223–1232.
Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova
AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day
LA, et al. 2009. Homodimerization controls the fibroblast
growth factor 9 subfamily’s receptor binding and heparan sul-
fate-dependent diffusion in the extracellular matrix.Mol Cell
Biol 29: 4663–4678.
Kanazawa H, Tanaka H, Inoue M, Yamanaka Y, Namba N, Seino
Y. 2003. Efficacy of growth hormone therapy for patients with
skeletal dysplasia. J Bone Miner Metab 21: 307–310.
Kanazawa S, Fujiwara T, Matsuzaki S, Shingaki K, Taniguchi M,
Miyata S, Tohyama M, Sakai Y, Yano K, Hosokawa K, et al.
2010. bFGF regulates PI3-kinase–Rac1–JNK pathway and pro-
motes fibroblast migration in wound healing. PLoS One 5:
e12228.
Kant SG,Cervenkova I, Balek L, Trantirek L, SantenGW, de Vries
MC, van Duyvenvoorde HA, van der Wielen MJ, Verkerk AJ,
Uitterlinden AG, et al. 2015. A novel variant of FGFR3 causes
proportionate short stature. Eur J Endocrinol 172: 763–770.
Karlsson C, ThornemoM, Henriksson HB, Lindahl A. 2009. Iden-
tification of a stem cell niche in the zone of Ranvierwithin the
knee joint. J Anat 215: 355–363.
Karolak MR, Yang X, Elefteriou F. 2015. FGFR1 signaling in hy-
pertrophic chondrocytes is attenuated by the Ras-GAP neuro-
fibromin during endochondral bone formation. Hum Mol
Genet 24: 2552–2564.
Kawaguchi H, Pilbeam CC, Gronowicz G, Abreu C, Fletcher BS,
Herschman HR, Raisz LG, HurleyMM. 1995. Transcriptional
induction of prostaglandin G/H synthase-2 by basic fibroblast
growth factor. J Clin Invest 96: 923–930.
Kawaguchi H, Chikazu D, Nakamura K, Kumegawa M, Hakeda
Y. 2000. Direct and indirect actions of fibroblast growth factor
2 on osteoclastic bone resorption in cultures. J BoneMiner Res
15: 466–473.
Kawaguchi H, Oka H, Jingushi S, Izumi T, Fukunaga M, Sato K,
Matsushita T, Nakamura K. 2010. A local application of re-
combinant human fibroblast growth factor-2 for tibial shaft
fractures: a randomized, placebo-controlled trial. J BoneMiner
Res 25: 2735–2743.
Kim HJ, Rice DP, Kettunen PJ, Thesleff I. 1998. FGF-, BMP- and
Shh-mediated signalling pathways in the regulation of cranial
suture morphogenesis and calvarial bone development. De-
velopment 125: 1241–1251.
Kim HJ, Kim JH, Bae SC, Choi JY, Kim HJ, Ryoo HM. 2003. The
protein kinase C pathway plays a central role in the fibroblast
growth factor-stimulated expression and transactivation ac-
tivity of Runx2. J Biol Chem 278: 319–326.
Kim JM, Shin HI, Cha SS, Lee CS, Hong BS, Lim S, Jang HJ, Kim J,
YangYR, KimYH, et al. 2012.DJ-1 promotes angiogenesis and
osteogenesis by activating FGF receptor-1 signaling. Nat
Commun 3: 1296.
KodamaN,NagataM,TabataY,OzekiM,NinomiyaT, Takagi R.
2009. A local bone anabolic effect of rhFGF2-impregnated gel-
atin hydrogel by promoting cell proliferation and coordinating
osteoblastic differentiation. Bone 44: 699–707.
Kolupaeva V, Laplantine E, Basilico C. 2008. PP2A-mediated
dephosphorylation of p107 plays a critical role in chondrocyte
cell cycle arrest by FGF. PLoS One 3: e3447.
Kolupaeva V, Daempfling L, Basilico C. 2013. The B55α regulato-
ry subunit of protein phosphatase 2A mediates fibroblast
growth factor-induced p107 dephosphorylation and growth ar-
rest in chondrocytes. Mol Cell Biol 33: 2865–2878.
KomakiH, Tanaka T, ChazonoM, Kikuchi T. 2006. Repair of seg-
mental bone defects in rabbit tibiae using a complex of β-tri-
calcium phosphate, type I collagen, and fibroblast growth
factor-2. Biomaterials 27: 5118–5126.
Kosher RA, KulykWM, Gay SW. 1986. Collagen gene expression
during limb cartilage differentiation. J Cell Biol 102:
1151–1156.
Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi
D, Lax I, Schlessinger J. 1997. A lipid-anchored Grb2-binding
protein that links FGF-receptor activation to the Ras/MAPK
signaling pathway. Cell 89: 693–702.
Kozhemyakina E, Lassar AB, Zelzer E. 2015. A pathway to bone:
signaling molecules and transcription factors involved in
chondrocyte development and maturation. Development
142: 817–831.
Krejci P. 2014. The paradox of FGFR3 signaling in skeletal dyspla-
sia: why chondrocytes growth arrest while other cells over
proliferate.Mutat Res Rev Mutat Res 759: 40–48.
Krejci P, Salazar L, Goodridge HS, Kashiwada TA, Schibler MJ,
Jelinkova P, Thompson LM, Wilcox WR. 2008a. STAT1 and
STAT3 do not participate in FGF-mediated growth arrest in
chondrocytes. J Cell Sci 121: 272–281.
Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A,
Thompson LM, Bryja V, Kozubik A, WilcoxWR. 2008b. Anal-
ysis of STAT1 activation by six FGFR3 mutants associated
with skeletal dysplasia undermines dominant role of STAT1
in FGFR3 signaling in cartilage. PLoS One 3: e3961.
Krejci P, Aklian A, KauckaM, Sevcikova E, Prochazkova J,Masek
JK,Mikolka P, Pospisilova T, SpoustovaT,WeisM, et al. 2012.
Receptor tyrosine kinases activate canonical WNT/β-catenin
signaling via MAP kinase/LRP6 pathway and direct β-catenin
phosphorylation. PLoS One 7: e35826.
Kuhn LT, Ou G, Charles L, Hurley MM, Rodner CM, Gronowicz
G. 2013. Fibroblast growth factor-2 and bone morphogenetic
protein-2 have a synergistic stimulatory effect on bone forma-
tion in cell cultures from elderly mouse and human bone. J
Gerontol A Biol Sci Med Sci 68: 1170–1180.
Kumar D, Lassar AB. 2014. Fibroblast growth factor maintains
chondrogenic potential of limb bud mesenchymal cells by
modulating DNMT3A recruitment. Cell Rep 8: 1419–1431.
Kurimchak A, Haines DS, Garriga J, Wu S, De Luca F, Sweredoski
MJ, Deshaies RJ, Hess S, Grana X. 2013. Activation of p107 by
fibroblast growth factor, which is essential for chondrocyte
cell cycle exit, is mediated by the protein phosphatase
2A/B55α holoenzyme.Mol Cell Biol 33: 3330–3342.
Kuro-o M. 2008. Endocrine FGFs and Klothos: emerging con-
cepts. Trends Endocrinol Metab 19: 239–245.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Ro-
senblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, et al.
Ornitz and Marie
1480 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
2006. Regulation of fibroblast growth factor-23 signaling by
klotho. J Biol Chem 281: 6120–6123.
Kwan MD, Sellmyer MA, Quarto N, Ho AM, Wandless TJ, Long-
akerMT. 2011. Chemical control of FGF-2 release for promot-
ing calvarial healing with adipose stem cells. J Biol Chem 286:
11307–11313.
Kyono A, Avishai N, Ouyang Z, Landreth GE,Murakami S. 2012.
FGF and ERK signaling coordinately regulate mineralization-
related genes and play essential roles in osteocyte differentia-
tion. J Bone Miner Metab 30: 19–30.
Laederich MB, Horton WA. 2012. FGFR3 targeting strategies for
achondroplasia. Expert Rev Mol Med 14: e11.
Lamothe B, Yamada M, Schaeper U, Birchmeier W, Lax I, Schles-
singer J. 2004. The docking protein Gab1 is an essential com-
ponent of an indirect mechanism for fibroblast growth factor
stimulation of the phosphatidylinositol 3-kinase/Akt antia-
poptotic pathway.Mol Cell Biol 24: 5657–5666.
Laplantine E, Rossi F, SahniM, Basilico C, Cobrinik D. 2002. FGF
signaling targets the pRb-related p107 and p130 proteins to in-
duce chondrocyte growth arrest. J Cell Biol 158: 741–750.
Lazarus JE,HegdeA, AndradeAC,NilssonO, Baron J. 2007. Fibro-
blast growth factor expression in the postnatal growth plate.
Bone 40: 577–586.
Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A,
Bonaventure J. 1998. Fibroblast growth factor receptor 3muta-
tions promote apoptosis but do not alter chondrocyte prolifer-
ation in thanatophoric dysplasia. J Biol Chem 273:
13007–13014.
Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J.
2004. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 cor-
relates with phenotypic severity and defective chondrocyte
differentiation in FGFR3-related chondrodysplasias. Bone
34: 26–36.
Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor ty-
rosine kinases. Cell 141: 1117–1134.
Lemonnier J, Hay E, Delannoy P, Fromigue O, Lomri A, Modrow-
ski D, Marie PJ. 2001a. Increased osteoblast apoptosis in apert
craniosynostosis: role of protein kinase C and interleukin-1.
Am J Pathol 158: 1833–1842.
Lemonnier J, Hay E, Delannoy P, Lomri A, Modrowski D, Caver-
zasio J,Marie PJ. 2001b. Role ofN-cadherin and protein kinase
C in osteoblast gene activation induced by the S252W fibro-
blast growth factor receptor 2 mutation in Apert craniosynos-
tosis. J Bone Miner Res 16: 832–845.
Lenton KA, Nacamuli RP, Wan DC, Helms JA, Longaker MT.
2005. Cranial suture biology. Curr Top Dev Biol 66: 287–328.
Li C, Xu X, Nelson DK, Williams T, Kuehn MR, Deng CX. 2005.
FGFR1 function at the earliest stages of mouse limb develop-
ment plays an indispensable role in subsequent autopod mor-
phogenesis. Development 132: 4755–4764.
LiM, Seki Y, Freitas PH,NagataM, Kojima T, Sultana S, Ubaidus
S, Maeda T, Shimomura J, Henderson JE, et al. 2010. FGFR3
down-regulates PTH/PTHrP receptor gene expression by me-
diating JAK/STAT signaling in chondrocytic cell line. J Elec-
tron Microsc (Tokyo) 59: 227–236.
Li Y, AhrensMJ,WuA, Liu J, Dudley AT. 2011. Calcium/calmod-
ulin-dependent protein kinase II activity regulates the prolif-
erative potential of growth plate chondrocytes.
Development 138: 359–370.
Lian JB, Stein GS, JavedA, vanWijnen AJ, Stein JL,MontecinoM,
HassanMQ, Gaur T, Lengner CJ, Young DW. 2006. Networks
and hubs for the transcriptional control of osteoblastogenesis.
Rev Endocr Metab Disord 7: 1–16.
Liao E. 2013. FGF23 associated bone diseases. FrontMed 7: 65–80.
Liao S, Porter D, Scott A, Newman G, Doetschman T, Schultz Jel
J. 2007. The cardioprotective effect of the low molecular
weight isoform of fibroblast growth factor-2: the role of JNK
signaling. J Mol Cell Cardiol 42: 106–120.
Lim J, Tu X, Choi K, Akiyama H, Mishina Y, Long F. 2015. BMP-
Smad4 signaling is required for precartilaginous mesenchy-
mal condensation independent of Sox9 in the mouse. Dev
Biol 400: 132–138.
Liu Y, Olsen BR. 2014. Distinct VEGF functions during bone de-
velopment and homeostasis.Arch Immunol Ther Exp (Warsz)
62: 363–368.
LiuZ, Xu J, Colvin JS, OrnitzDM. 2002. Coordination of chondro-
genesis and osteogenesis by fibroblast growth factor 18.Genes
Dev 16: 859–869.
Liu Z, Lavine KJ, Hung IH, Ornitz DM. 2007. FGF18 is required
for early chondrocyte proliferation, hypertrophy and vascular
invasion of the growth plate. Dev Biol 302: 80–91.
Liu J, Kwon TG, Nam HK, Hatch NE. 2013a. Craniosynostosis-
associated Fgfr2(C342Y) mutant bone marrow stromal cells
exhibit cell autonomous abnormalities in osteoblast differen-
tiation and bone formation. Biomed Res Int 2013: 292506.
Liu J, NamHK,Wang E, HatchNE. 2013b. Further analysis of the
Crouzon mouse: effects of the FGFR2(C342Y) mutation are
cranial bone-dependent. Calcif Tissue Int 92: 451–466.
Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Mun-
nichA, Renier D,Marie PJ. 1998. Increased calvaria cell differ-
entiation and bone matrix formation induced by fibroblast
growth factor receptor 2 mutations in Apert syndrome. J
Clin Invest 101: 1310–1317.
Lomri A, Lemonnier J, Delannoy P, Marie PJ. 2001. Increased ex-
pression of protein kinase Cα, interleukin-1α, and RhoA gua-
nosine 5′-triphosphatase in osteoblasts expressing the
Ser252Trp fibroblast growth factor 2 Apert mutation: identifi-
cation by analysis of complementary DNAmicroarray. J Bone
Miner Res 16: 705–712.
Long F. 2012. Building strong bones: molecular regulation of the
osteoblast lineage. Nat Rev Mol Cell Biol 13: 27–38.
Long F, OrnitzDM. 2013.Development of the endochondral skel-
eton. Cold Spring Harb Perspect Biol 5: 1–20.
Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppe-
neer T, Wendt DJ, Bell SM, Bullens S, Bunting S, et al. 2012.
Evaluation of the therapeutic potential of a CNP analog in a
Fgfr3 mouse model recapitulating achondroplasia. Am J
Hum Genet 91: 1108–1114.
Lu X, Su N, Yang J, Huang W, Li C, Zhao L, He Q, Du X, Shen Y,
Chen B, et al. 2009. Fibroblast growth factor receptor 1 regu-
lates the differentiation and activation of osteoclasts through
Erk1/2 pathway. Biochem Biophys Res Commun 390:
494–499.
Maes C, Kobayashi T, SeligMK, Torrekens S, Roth SI,Mackem S,
Carmeliet G, Kronenberg HM. 2010. Osteoblast precursors,
but not mature osteoblasts, move into developing and frac-
tured bones along with invading blood vessels. Dev Cell 19:
329–344.
Makrythanasis P, TemtamyS, AglanMS,OtaifyGA,HamamyH,
Antonarakis SE. 2014. A novel homozygous mutation in
FGFR3 causes tall stature, severe lateral tibial deviation, sco-
liosis, hearing impairment, camptodactyly, and arachnodac-
tyly. Hum Mutat 35: 959–963.
Mansukhani A, Bellosta P, Sahni M, Basilico C. 2000. Signaling
by fibroblast growth factors (FGF) and fibroblast growth factor
receptor 2 (FGFR2)-activating mutations blocks mineraliza-
tion and induces apoptosis in osteoblasts. J Cell Biology 149:
1297–1308.
FGF signaling in skeletal development and disease
GENES & DEVELOPMENT 1481
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico
C. 2005. Sox2 induction by FGF and FGFR2 activating muta-
tions inhibits Wnt signaling and osteoblast differentiation. J
Cell Biol 168: 1065–1076.
Mariani FV, Ahn CP, Martin GR. 2008. Genetic evidence that
FGFs have an instructive role in limb proximal-distal pattern-
ing. Nature 453: 401–405.
Marie PJ. 2008. Transcription factors controlling osteoblastogen-
esis. Arch Biochem Biophys 473: 98–105.
Marie PJ. 2015. Osteoblast dysfunctions in bone diseases: from
cellular and molecular mechanisms to therapeutic strategies.
Cell Mol Life Sci 72: 1347–1361.
Marie PJ, Coffin JD, Hurley MM. 2005. FGF and FGFR signaling
in chondrodysplasias and craniosynostosis. J Cell Biochem
96: 888–896.
Marie PJ, Kaabeche K, GuenouH. 2008. Roles of FGFR2 and twist
in human craniosynostosis: insights from genetic mutations
in cranial osteoblasts. Front Oral Biol 12: 144–159.
Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, Quarles LD.
2011. Bone proteins PHEX and DMP1 regulate fibroblastic
growth factor Fgf23 expression in osteocytes through a com-
mon pathway involving FGF receptor (FGFR) signaling.
FASEB J 25: 2551–2562.
Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P,
MartinezA, Casal JI. 2005. Targeting the extracellular domain
of fibroblast growth factor receptor 3with human single-chain
Fv antibodies inhibits bladder carcinoma cell line prolifera-
tion. Clin Cancer Res 11: 6280–6290.
MaruyamaT,MirandoAJ, DengCX, HsuW. 2010. The balance of
WNT and FGF signaling influences mesenchymal stem cell
fate during skeletal development. Sci Signal 3: ra40.
Matsushita T, Chan YY, Kawanami A, Balmes G, Landreth GE,
Murakami S. 2009a. Extracellular signal-regulated kinase 1
(ERK1) and ERK2 play essential roles in osteoblast differenti-
ation and in supporting osteoclastogenesis. Mol Cell Biol 29:
5843–5857.
Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bukulmez H,
Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, et al.
2009b. FGFR3 promotes synchondrosis closure and fusion of
ossification centers through the MAPK pathway. Hum Mol
Genet 18: 227–240.
Matsushita M, Kitoh H, Ohkawara B, Mishima K, Kaneko H, Ito
M,MasudaA, IshiguroN,OhnoK. 2013.Meclozine facilitates
proliferation and differentiation of chondrocytes by attenuat-
ing abnormally activated FGFR3 signaling in achondroplasia.
PLoS One 8: e81569.
Matsushita M, Hasegawa S, Kitoh H, Mori K, Ohkawara B,
Yasoda A, Masuda A, Ishiguro N, Ohno K. 2015. Meclozine
promotes longitudinal skeletal growth in transgenic mice
with achondroplasia carrying a gain-of-function mutation in
the FGFR3 gene. Endocrinology 156: 548–554.
McDowell LM, Frazier BA, StudelskaDR,GiljumK, Chen J, Liu J,
Yu K, Ornitz DM, Zhang L. 2006. Inhibition or activation of
Apert syndrome FGFR2 (S252W) signaling by specific glycos-
aminoglycans. J Biol Chem 281: 6924–6930.
McEwen DG, Green RP, Naski MC, Towler DA, Ornitz DM.
1999. Fibroblast growth factor receptor 3 gene transcription
is suppressed by cyclic adenosine 3′,5′-monophosphate: iden-
tification of a chondrocytic regulatory element. J Biol Chem
274: 30934–30942.
Melville H, Wang Y, Taub PJ, Jabs EW. 2010. Genetic basis of po-
tential therapeutic strategies for craniosynostosis. Am J Med
Genet A 152A: 3007–3015.
Merrill AE, Sarukhanov A, Krejci P, Idoni B, Camacho N, Estrada
KD, Lyons KM, Deixler H, Robinson H, Chitayat D, et al.
2012. Bent bone dysplasia-FGFR2 type, a distinct skeletal dis-
order, has deficient canonical FGF signaling.Am JHumGenet
90: 550–557.
Miraoui H, Marie PJ. 2010. Fibroblast growth factor receptor sig-
naling crosstalk in skeletogenesis. Sci Signal 3: re9.
Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie
PJ. 2009. Fibroblast growth factor receptor 2 promotes osteo-
genic differentiation in mesenchymal cells via ERK1/2 and
protein kinase C signaling. J Biol Chem 284: 4897–4904.
Miraoui H, Ringe J, Haupl T, Marie PJ. 2010a. Increased EGF- and
PDGFα-receptor signaling by mutant FGF-receptor 2 contrib-
utes to osteoblast dysfunction in Apert craniosynostosis.
Hum Mol Genet 19: 1678–1689.
Miraoui H, SevereN, Vaudin P, Pages JC,Marie PJ. 2010b.Molec-
ular silencing of Twist1 enhances osteogenic differentiation of
murine mesenchymal stem cells: implication of FGFR2 sig-
naling. J Cell Biochem 110: 1147–1154.
Miura K, Kim OH, Lee HR, Namba N, Michigami T, Yoo WJ,
Choi IH, Ozono K, Cho TJ. 2014. Overgrowth syndrome asso-
ciated with a gain-of-functionmutation of the natriuretic pep-
tide receptor 2 (NPR2) gene. Am J Med Genet A 164A:
156–163.
MoenningA, Jager R, EgertA, KressW,Wardelmann E, SchorleH.
2009. Sustained platelet-derived growth factor receptor α sig-
naling in osteoblasts results in craniosynostosis by overacti-
vating the phospholipase C-γ pathway. Mol Cell Biol 29:
881–891.
Molteni A,Modrowski D,HottM,Marie PJ. 1999a. Alterations of
matrix- and cell-associated proteoglycans inhibit osteogenesis
and growth response to fibroblast growth factor-2 in cultured
rat mandibular condyle and calvaria. Cell Tissue Res 295:
523–536.
Molteni A, Modrowski D, Hott M, Marie PJ. 1999b. Differential
expression of fibroblast growth factor receptor-1, -2, and -3
and syndecan-1, -2, and -4 in neonatal rat mandibular condyle
and calvaria during osteogenic differentiation in vitro. Bone
24: 337–347.
Montero A, Okada Y, TomitaM, ItoM, TsurukamiH, Nakamura
T, Doetschman T, Coffin JD, HurleyMM. 2000. Disruption of
the fibroblast growth factor-2 gene results in decreased bone
mass and bone formation. J Clin Invest 105: 1085–1093.
Moon AM, Guris DL, Seo JH, Li L, Hammond J, Talbot A, Ima-
moto A. 2006. Crkl deficiency disrupts Fgf8 signaling in a
mouse model of 22q11 deletion syndromes. Dev Cell 10:
71–80.
Moore R, Ferretti P, Copp A, Thorogood P. 2002. Blocking endog-
enous FGF-2 activity prevents cranial osteogenesis. Dev Biol
243: 99–114.
Morita J, Nakamura M, Kobayashi Y, Deng CX, Funato N, Mor-
iyama K. 2014. Soluble form of FGFR2 with S252W partially
prevents craniosynostosis of the apert mouse model. Dev
Dyn 243: 560–567.
Motch Perrine SM, Cole TM III, Martinez-Abadias N, Aldridge K,
Jabs EW, Richtsmeier JT. 2014. Craniofacial divergence by dis-
tinct prenatal growth patterns in Fgfr2 mutant mice. BMC
Dev Biol 14: 8.
Mugniery E, Dacquin R, Marty C, Benoist-Lasselin C, de Verne-
joul MC, Jurdic P, Munnich A, Geoffroy V, Legeai-Mallet L.
2012. An activating Fgfr3mutation affects trabecular bone for-
mation via a paracrine mechanism during growth. Hum Mol
Genet 21: 2503–2513.
Murakami S, Kan M, McKeehan WL, de Crombrugghe B. 2000.
Up-regulation of the chondrogenic Sox9 gene by fibroblast
growth factors is mediated by the mitogen-activated protein
kinase pathway. Proc Natl Acad Sci 97: 1113–1118.
Ornitz and Marie
1482 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, De
Crombrugghe B. 2004. Constitutive activation of MEK1 in
chondrocytes causes Stat1-independent achondroplasia-like
dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Genes Dev 18: 290–305.
Naganawa T, Xiao L, Coffin JD, Doetschman T, Sabbieti MG,
Agas D, Hurley MM. 2008. Reduced expression and function
of bone morphogenetic protein-2 in bones of Fgf2 null mice.
J Cell Biochem 103: 1975–1988.
Nah HD, Rodgers BJ, Kulyk WM, Kream BE, Kosher RA, Upholt
WB. 1988. In situ hybridization analysis of the expression of
the type II collagen gene in the developing chicken limb
bud. Coll Relat Res 8: 277–294.
Nakajima F, Nakajima A, Ogasawara A, Moriya H, Yamazaki M.
2007. Effects of a single percutaneous injection of basic fibro-
blast growth factor on the healing of a closed femoral shaft
fracture in the rat. Calcif Tissue Int 81: 132–138.
Nakamura T, Hara Y, Tagawa M, Tamura M, Yuge T, Fukuda H,
Nigi H. 1998. Recombinant human basic fibroblast growth
factor accelerates fracture healing by enhancing callus remod-
eling in experimental dog tibial fracture. J Bone Miner Res 13:
942–949.
Nakamura Y, Tensho K, Nakaya H, Nawata M, Okabe T, Waki-
tani S. 2005. Low dose fibroblast growth factor-2 (FGF-2) en-
hances bone morphogenetic protein-2 (BMP-2)-induced
ectopic bone formation in mice. Bone 36: 399–407.
Nakao K, Osawa K, Yasoda A, Yamanaka S, Fujii T, Kondo E,
Koyama N, Kanamoto N, Miura M, Kuwahara K, et al. 2015.
The Local CNP/GC-B system in growth plate is responsible
for physiological endochondral bone growth. Sci Rep 5: 10554.
Naski MC, Wang Q, Xu J, Ornitz DM. 1996. Graded activation of
fibroblast growth factor receptor 3 by mutations causing
achondroplasia and thanatophoric dysplasia. Nat Genet 13:
233–237.
Naski MC, Colvin JS, Coffin JD, Ornitz DM. 1998. Repression of
hedgehog signaling and BMP4 expression in growth plate car-
tilage by fibroblast growth factor receptor 3. Development
125: 4977–4988.
Neben CL, Idoni B, Salva JE, Tuzon CT, Rice JC, Krakow D, Mer-
rill AE. 2014. Bent bone dysplasia syndrome reveals nucleolar
activity for FGFR2 in ribosomalDNA transcription.HumMol
Genet 23: 5659–5671.
Niger C, Luciotti MA, Buo AM, Hebert C, Ma V, Stains JP. 2013.
The regulation of runt-related transcription factor 2 by fibro-
blast growth factor-2 and connexin43 requires the inositol pol-
yphosphate/protein kinase Cδ cascade. J Bone Miner Res 28:
1468–1477.
Noonan KJ, Hunziker EB, Nessler J, Buckwalter JA. 1998. Chang-
es in cell, matrix compartment, and fibrillar collagen volumes
between growth-plate zones. J Orthop Res 16: 500–508.
Oh CD, Lu Y, Liang S, Mori-Akiyama Y, Chen D, de Crom-
brugghe B, Yasuda H. 2014. SOX9 regulates multiple genes
in chondrocytes, including genes encoding ECM proteins,
ECM modification enzymes, receptors, and transporters.
PLoS One 9: e107577.
OhbayashiN, ShibayamaM, Kurotaki Y, ImanishiM, Fujimori T,
Itoh N, Takada S. 2002. FGF18 is required for normal cell pro-
liferation and differentiation during osteogenesis and chon-
drogenesis. Genes Dev 16: 870–879.
Okada Y, Montero A, Zhang X, Sobue T, Lorenzo J, Doetschman
T,Coffin JD,HurleyMM. 2003. Impaired osteoclast formation
in bonemarrow cultures of Fgf2 null mice in response to para-
thyroid hormone. J Biol Chem 278: 21258–21266.
Olney RC, Prickett TC, Espiner EA, Mackenzie WG, Duker AL,
Ditro C, Zabel B, Hasegawa T, Kitoh H, Aylsworth AS, et al.
2015. C-type natriuretic peptide plasma levels are elevated
in subjects with achondroplasia, hypochondroplasia, and tha-
natophoric dysplasia. J Clin Endocrinol Metab 100:
E355–E359.
Ono N, Ono W, Nagasawa T, Kronenberg HM. 2014. A subset of
chondrogenic cells provides early mesenchymal progenitors
in growing bones. Nat Cell Biol 16: 1157–1167.
Opperman LA. 2000. Cranial sutures as intramembranous bone
growth sites [Review]. Dev Dyn 219: 472–485.
Ornitz DM. 2005. FGF signaling in the developing endochondral
skeleton. Cytokine Growth Factor Rev 16: 205–213.
Ornitz DM, ItohN. 2015. The Fibroblast Growth Factor signaling
pathway.Wiley Interdiscip Rev Dev Biol 4: 215–266.
OrnitzDM,Marie PJ. 2002. FGF signaling pathways in endochon-
dral and intramembranous bone development and human ge-
netic disease. Genes Dev 16: 1446–1465.
Orr-Urtreger A, Givol D, Yayon A, Yarden Y, Lonai P. 1991.
Developmental expression of two murine fibroblast growth
factor receptors, flg and bek. Development 113: 1419–1434.
Ozasa A, Komatsu Y, Yasoda A, Miura M, Sakuma Y, Nakatsuru
Y, Arai H, Itoh N, Nakao K. 2005. Complementary antagonis-
tic actions between C-type natriuretic peptide and the MAPK
pathway through FGFR-3 in ATDC5 cells. Bone 36:
1056–1064.
Pannier S, Couloigner V, Messaddeq N, Elmaleh-Berges M, Mun-
nich A, Romand R, Legeai-Mallet L. 2009. Activating Fgfr3
Y367C mutation causes hearing loss and inner ear defect in
a mouse model of chondrodysplasia. Biochim Biophys Acta
1792: 140–147.
Park OJ, Kim HJ, Woo KM, Baek JH, Ryoo HM. 2010. FGF2-acti-
vated ERKmitogen-activated protein kinase enhances Runx2
acetylation and stabilization. J Biol Chem 285: 3568–3574.
Peake NJ, Hobbs AJ, Pingguan-Murphy B, Salter DM, Berenbaum
F, Chowdhury TT. 2014. Role of C-type natriuretic peptide
signalling in maintaining cartilage and bone function.Osteo-
arthritis Cartilage 22: 1800–1807.
Perlyn CA, Morriss-Kay G, Darvann T, Tenenbaum M, Ornitz
DM. 2006. A model for the pharmacological treatment of
crouzon syndrome. Neurosurgery 59: 210–215.
Peters KG,Werner S, ChenG,Williams LT. 1992. Two FGF recep-
tor genes are differentially expressed in epithelial and mesen-
chymal tissues during limb formation and organogenesis in
the mouse. Development 114: 233–243.
Peters K, Ornitz D, Werner S, Williams L. 1993. Unique expres-
sion pattern of the FGF receptor 3 gene during mouse organo-
genesis. Dev Biol 155: 423–430.
Priore R, Dailey L, Basilico C. 2006. Downregulation of Akt activ-
ity contributes to the growth arrest induced by FGF in chon-
drocytes. J Cell Physiol 207: 800–808.
Purcell P, Joo BW, Hu JK, Tran PV, Calicchio ML, O’Connell DJ,
Maas RL, Tabin CJ. 2009. Temporomandibular joint forma-
tion requires two distinct hedgehog-dependent steps. Proc
Natl Acad Sci 106: 18297–18302.
Qi H, Jin M, Duan Y, Du X, Zhang Y, Ren F, Wang Y, Tian Q,
Wang X, Wang Q, et al. 2014. FGFR3 induces degradation of
BMP type I receptor to regulate skeletal development. Bio-
chim Biophys Acta 1843: 1237–1247.
Qing J, Du X, Chen Y, Chan P, Li H,Wu P,Marsters S, Stawicki S,
Tien J, Totpal K, et al. 2009. Antibody-based targeting of
FGFR3 in bladder carcinoma and t(4;14)-positivemultiplemy-
eloma in mice. J Clin Invest 119: 1216–1229.
Quarles LD. 2012. Skeletal secretion of FGF-23 regulates phos-
phate and vitamin D metabolism. Nat Rev Endocrinol 8:
276–286.
FGF signaling in skeletal development and disease
GENES & DEVELOPMENT 1483
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Quarto N, Behr B, Li S, Longaker MT. 2009. Differential FGF li-
gands and FGF receptors expression pattern in frontal and pa-
rietal calvarial bones. Cells Tissues Organs 190: 158–169.
Raucci A, Laplantine E, Mansukhani A, Basilico C. 2004. Activa-
tion of the ERK1/2 and p38 mitogen-activated protein kinase
pathways mediates fibroblast growth factor-induced growth
arrest of chondrocytes. J Biol Chem 279: 1747–1756.
Reinhold MI, Naski MC. 2007. Direct interactions of Runx2 and
canonical Wnt signaling induce FGF18. J Biol Chem 282:
3653–3663.
Reinhold MI, Abe M, Kapadia RM, Liao Z, Naski MC. 2004.
FGF18 represses noggin expression and is induced by calci-
neurin. J Biol Chem 279: 38209–38219.
Rice DP, Rice R. 2008. Locate, condense, differentiate, grow and
confront: developmental mechanisms controlling intramem-
branous bone and suture formation and function. Front Oral
Biol 12: 22–40.
Rice DP, Kim HJ, Thesleff I. 1999. Apoptosis in murine calvarial
bone and suture development. Eur J Oral Sci 107: 265–275.
Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L,
Maxson RE, Thesleff I. 2000. Integration of FGF and TWIST
in calvarial bone and suture development. Development
127: 1845–1855.
Rice DP, Rice R, Thesleff I. 2003. Fgfr mRNA isoforms in cranio-
facial bone development. Bone 33: 14–27.
Robinson D, Hasharoni A, Cohen N, Yayon A, Moskowitz RM,
Nevo Z. 1999. Fibroblast growth factor receptor-3 as a marker
for precartilaginous stem cells. Clin Orthop Relat Res:
S163–S175.
Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetsch-
man T, Hurley MM. 2009. Endogenous FGF-2 is critically im-
portant in PTH anabolic effects on bone. J Cell Physiol 219:
143–151.
SabbietiMG,AgasD,Marchetti L, Coffin JD, Xiao L,HurleyMM.
2013. BMP-2 differentiallymodulates FGF-2 isoform effects in
osteoblasts from newborn transgenic mice. Endocrinology
154: 2723–2733.
Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D,
Basilico C. 1999. FGF signaling inhibits chondrocyte prolifer-
ation and regulates bone development through the STAT-1
pathway. Genes Dev 13: 1361–1366.
Saran U, Gemini Piperni S, Chatterjee S. 2014. Role of angiogen-
esis in bone repair. Arch Biochem Biophys 561: 109–117.
Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases.
Cell 103: 211–225.
Schlessinger J. 2003. Signal transduction. Autoinhibition control.
Science 300: 750–752.
Schmidt MH, Dikic I. 2005. The Cbl interactome and its func-
tions. Nat Rev Mol Cell Biol 6: 907–918.
Schmid GJ, Kobayashi C, Sandell LJ, Ornitz DM. 2009. Fibroblast
growth factor expression during skeletal fracture healing in
mice. Dev Dyn 238: 766–774.
Sebastian A, Matsushita T, Kawanami A, Mackem S, Landreth
GE, Murakami S. 2011. Genetic inactivation of ERK1 and
ERK2 in chondrocytes promotes bone growth and enlarges
the spinal canal. J Orthop Res 29: 375–379.
Senarath-Yapa K, Chung MT, McArdle A, Wong VW, Quarto N,
Longaker MT, Wan DC. 2012. Craniosynostosis: molecular
pathways and future pharmacologic therapy. Organogenesis
8: 103–113.
Severe N, Dieudonne FX, Marie PJ. 2013. E3 ubiquitin ligase-me-
diated regulation of bone formation and tumorigenesis. Cell
Death Dis 4: e463.
Sheeba CJ, Andrade RP, Duprez D, Palmeirim I. 2010. Compre-
hensive analysis of fibroblast growth factor receptor expres-
sion patterns during chick forelimb development. Int J Dev
Biol 54: 1517–1526.
Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ,
Bocian M, Winokur ST, Wasmuth JJ. 1994. Mutations in the
transmembrane domain of FGFR3 cause the most common
genetic form of dwarfism, achondroplasia. Cell 78: 335–342.
Shimoaka T, Ogasawara T, Yonamine A, Chikazu D, Kawano H,
Nakamura K, Itoh N, Kawaguchi H. 2002. Regulation of oste-
oblast, chondrocyte, and osteoclast functions by fibroblast
growth factor (FGF)-18 in comparison with FGF-2 and FGF-
10. J Biol Chem 277: 7493–7500.
Shimokawa K, Kimura-Yoshida C, Nagai N, Mukai K, Matsubara
K, Watanabe H, Matsuda Y, Mochida K, Matsuo I. 2011. Cell
surface heparan sulfate chains regulate local reception of
FGF signaling in the mouse embryo. Dev Cell 21: 257–272.
Shinde DN, Elmer DP, Calabrese P, Boulanger J, ArnheimN, Tie-
mann-Boege I. 2013.Newevidence for positive selection helps
explain the paternal age effect observed in achondroplasia.
Hum Mol Genet 22: 4117–4126.
Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. 2007. RNA
interference and inhibition ofMEK–ERK signaling prevent ab-
normal skeletal phenotypes in a mousemodel of craniosynos-
tosis. Nat Genet 39: 1145–1150.
Shung CY, Ota S, Zhou ZQ, Keene DR, Hurlin PJ. 2012. Disrup-
tion of a Sox9–β-catenin circuit by mutant Fgfr3 in thanato-
phoric dysplasia type II. Hum Mol Genet 21: 4628–4644.
Smith LB, Dally MR, Sainz RD, Rodrigue KL, Oberbauer AM.
2006. Enhanced skeletal growth of sheep heterozygous for
an inactivated fibroblast growth factor receptor 3. J Anim Sci
84: 2942–2949.
Smith BN, Burton LJ, Henderson V, Randle DD, Morton DJ,
Smith BA, Taliaferro-Smith L, Nagappan P, Yates C, Zayza-
foon M, et al. 2014. Snail promotes epithelial mesenchymal
transition in breast cancer cells in part via activation of nucle-
ar ERK2. PLoS One 9: e104987.
Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C,
HortonWA, Fu XY. 1997. Activation of Stat1 bymutant fibro-
blast growth-factor receptor in thanatophoric dysplasia type II
dwarfism. Nature 386: 288–292.
SuN, SunQ, LiC, LuX,QiH,Chen S, Yang J, DuX, Zhao L,HeQ,
et al. 2010. Gain-of-functionmutation in FGFR3 inmice leads
to decreased bone mass by affecting both osteoblastogenesis
and osteoclastogenesis. Hum Mol Genet 19: 1199–1210.
Suzuki H, Suda N, Shiga M, Kobayashi Y, Nakamura M, Iseki S,
Moriyama K. 2012. Apert syndrome mutant FGFR2 and its
soluble form reciprocally alter osteogenesis of primary calva-
rial osteoblasts. J Cell Physiol 227: 3267–3277.
SzebenyiG, SavageMP,Olwin BB, Fallon JF. 1995. Changes in the
expression of fibroblast growth factor receptors mark distinct
stages of chondrogenesis in vitro and during chick limb skel-
etal patterning. Dev Dyn 204: 446–456.
Takai S, Tokuda H, Hanai Y, Harada A, Yasuda E, Matsushima-
Nishiwaki R, Kato H, Ogura S, Ohta T, Kozawa O. 2007. Neg-
ative regulation by p70 S6 kinase of FGF-2-stimulated VEGF
release through stress-activated protein kinase/c-JunN-termi-
nal kinase in osteoblasts. J Bone Miner Res 22: 337–346.
TanY, Rouse J, ZhangA, Cariati S, Cohen P, CombMJ. 1996. FGF
and stress regulate CREB and ATF-1 via a pathway involving
p38 MAP kinase and MAPKAP kinase-2. EMBO J 15:
4629–4642.
Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H,
Matsumoto T, Marie PJ, Moriyama K. 2004. A soluble form of
fibroblast growth factor receptor 2 (FGFR2) with S252Wmuta-
tion acts as an efficient inhibitor for the enhanced osteoblastic
Ornitz and Marie
1484 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
differentiation caused by FGFR2 activation in Apert syn-
drome. J Biol Chem 279: 45926–45934.
Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ,
Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth
JJ. 1995. Thanatophoric dysplasia (types I and II) caused by dis-
tinctmutations in fibroblast growth factor receptor 3.NatGe-
net 9: 321–328.
Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE,
McIntosh I, Szabo J, JiangW, Jabs EW,WilcoxWR, et al. 1999.
A novel skeletal dysplasiawith developmental delay and acan-
thosis nigricans is caused by a Lys650Met mutation in the fi-
broblast growth factor receptor 3 gene. Am J Hum Genet 64:
722–731.
Ten Berge D, Brugmann SA, Helms JA, Nusse R. 2008. Wnt and
FGF signals interact to coordinate growth with cell fate spec-
ification during limb development. Development 135:
3247–3257.
Teplyuk NM, Haupt LM, Ling L, Dombrowski C, Mun FK, Na-
than SS, Lian JB, Stein JL, Stein GS, Cool SM, et al. 2009.
The osteogenic transcription factor Runx2 regulates compo-
nents of the fibroblast growth factor/proteoglycan signaling
axis in osteoblasts. J Cell Biochem 107: 144–154.
Timsah Z, Ahmed Z, Lin CC, Melo FA, Stagg LJ, Leonard PG,
Jeyabal P, Berrout J, O’Neil RG, BogdanovM, et al. 2014. Com-
petition between Grb2 and Plcγ1 for FGFR2 regulates basal
phospholipase activity and invasion. Nat Struct Mol Biol 21:
180–188.
Torii S, KusakabeM,YamamotoT,MaekawaM,Nishida E. 2004.
Sef is a spatial regulator for Ras/MAP kinase signaling. Dev
Cell 7: 33–44.
Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak
PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC,
BamshadMJ. 2006. A novel mutation in FGFR3 causes camp-
todactyly, tall stature, and hearing loss (CATSHL) syndrome.
Am J Hum Genet 79: 935–941.
Tsang M, Dawid IB. 2004. Promotion and attenuation of FGF sig-
naling through the Ras–MAPK pathway. Sci STKE 2004: pe17.
Tsuji T, Kunieda T. 2005. A loss-of-function mutation in natri-
uretic peptide receptor 2 (Npr2) gene is responsible for dispro-
portionate dwarfism in cn/cn mouse. J Biol Chem 280:
14288–14292.
Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT,
Morriss-Kay GM, Wilkie AO. 2009. Skeletal analysis of the
Fgfr3(P244R) mouse, a genetic model for the Muenke cranio-
synostosis syndrome. Dev Dyn 238: 331–342.
Twigg SR, Vorgia E, McGowan SJ, Peraki I, Fenwick AL, Sharma
VP, Allegra M, Zaragkoulias A, Sadighi Akha E, Knight SJ,
et al. 2013. Reduced dosage of ERF causes complex craniosyn-
ostosis in humans andmice and links ERK1/2 signaling to reg-
ulation of osteogenesis. Nat Genet 45: 308–313.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H,
Okawa K, Fujita T, Fukumoto S, Yamashita T. 2006. Klotho
converts canonical FGF receptor into a specific receptor for
FGF23. Nature 444: 770–774.
Vajo Z, Francomano CA, Wilkin DJ. 2000. The molecular and ge-
netic basis of fibroblast growth factor receptor 3 disorders: the
achondroplasia family of skeletal dysplasias, Muenke cranio-
synostosis, and Crouzon syndromewith acanthosis nigricans.
Endocr Rev 21: 23–39.
Valverde-Franco G, Liu H, Davidson D, Chai S, Valderrama-Car-
vajal H, Goltzman D, Ornitz DM, Henderson JE. 2004. Defec-
tive bone mineralization and osteopenia in young adult
FGFR3−/− mice. Hum Mol Genet 13: 271–284.
Verheyden JM, Lewandoski M, Deng C, Harfe BD, Sun X. 2005.
Conditional inactivation of Fgfr1 in mouse defines its role in
limb bud establishment, outgrowth and digit patterning. De-
velopment 132: 4235–4245.
Wang Y, Spatz MK, Kannan K, Hayk H, Avivi A, Gorivodsky M,
Pines M, Yayon A, Lonai P, Givol D. 1999. A mouse model
for achondroplasia produced by targeting fibroblast growth
factor receptor 3. Proc Natl Acad Sci 96: 4455–4460.
Wang Q, Green RP, Zhao G, Ornitz DM. 2001. Differential regu-
lation of endochondral bone growth and joint development by
FGFR1 and FGFR3 tyrosine kinase domains. Development
128: 3867–3876.
Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP,
Richtsmeier JT, Leszl JM, Hill CA, et al. 2005. Abnormalities
in cartilage and bone development in the Apert syndrome
FGFR2(+/S252W) mouse. Development 132: 3537–3548.
Wang Y, Sun M, Uhlhorn VL, Zhou X, Peter I, Martinez-Abadias
N, Hill CA, Percival CJ, Richtsmeier JT, Huso DL, et al. 2010.
Activation of p38 MAPK pathway in the skull abnormalities
of Apert syndrome Fgfr2(+P253R) mice. BMCDev Biol 10: 22.
Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F.
2011. Mice lacking Nf1 in osteochondroprogenitor cells dis-
play skeletal dysplasia similar to patients with neurofibroma-
tosis type I. Hum Mol Genet 20: 3910–3924.
Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker
MT. 2003. The BMP antagonist noggin regulates cranial su-
ture fusion. Nature 422: 625–629.
Wendt DJ, Dvorak-Ewell M, Bullens S, Lorget F, Bell SM, Peng J,
Castillo S, Aoyagi-Scharber M, O’Neill CA, Krejci P, et al.
2015. Neutral endopeptidase-resistant C-type natriuretic pep-
tide variant represents a new therapeutic approach for treat-
ment of fibroblast growth factor receptor 3-related dwarfism.
J Pharmacol Exp Ther 353: 132–149.
Weng T, Yi L, Huang J, Luo F, Wen X, Du X, Chen Q, Deng C,
Chen D, Chen L. 2012. Genetic inhibition of FGFR1 in carti-
lage attenuates articular cartilage degeneration in adult mice.
Arthritis Rheum 64: 3982–3992.
White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa
S, Fields J, Yu X, ShawNJ,McLellanNJ, et al. 2005.Mutations
that cause osteoglophonic dysplasia define novel roles for
FGFR1 in bone elongation. Am J Hum Genet 76: 361–367.
White KE, Hum JM, Econs MJ. 2014. Hypophosphatemic rickets:
revealing novel control points for phosphate homeostasis.
Curr Osteoporos Rep 12: 252–262.
Wiedemann M, Trueb B. 2000. Characterization of a novel pro-
tein (FGFRL1) from human cartilage related to FGF receptors.
Genomics 69: 275–279.
Wilkie AO. 2007. Cancer drugs to treat birth defects. Nat Genet
39: 1057–1059.
Wilkin DJ, Szabo JK, Cameron R, Henderson S, Bellus GA, Mack
ML, Kaitila I, Loughlin J,MunnichA, Sykes B, et al. 1998.Mu-
tations in fibroblast growth-factor receptor 3 in sporadic cases
of achondroplasia occur exclusively on the paternally derived
chromosome. Am J Hum Genet 63: 711–716.
Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes
NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, et al.
2013. Pharmacological inhibition of fibroblast growth factor
(FGF) receptor signaling ameliorates FGF23-mediated hypo-
phosphatemic rickets. J Bone Miner Res 28: 899–911.
Wong A, Lamothe B, Lee A, Schlessinger J, Lax I. 2002. FRS2α at-
tenuates FGF receptor signaling by Grb2-mediated recruit-
ment of the ubiquitin ligase Cbl. Proc Natl Acad Sci 99:
6684–6689.
Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler DL, Love A, Rosen-
berg RD. 2003. The involvement of heparan sulfate (HS) in
FGF1/HS/FGFR1 signaling complex. J Biol Chem 278:
17121–17129.
FGF signaling in skeletal development and disease
GENES & DEVELOPMENT 1485
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ,
Cui B, Wang L, Lu SY, et al. 2009. Multiple synostoses syn-
drome is due to a missense mutation in exon 2 of FGF9
gene. Am J Hum Genet 85: 53–63.
Wu AL, Feng B, Chen MZ, Kolumam G, Zavala-Solorio J, Wyatt
SK, Gandham VD, Carano RA, Sonoda J. 2013. Antibody-me-
diated activation of FGFR1 induces FGF23 production and
hypophosphatemia. PLoS One 8: e57322.
Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. 2002. Fibro-
blast growth factor 2 induction of the osteocalcin gene re-
quires MAPK activity and phosphorylation of the osteoblast
transcription factor, Cbfa1/Runx2. J Biol Chem 277:
36181–36187.
Xiao L, Naganawa T, Obugunde E, Gronowicz G, Ornitz DM,
Coffin JD, Hurley MM. 2004. Stat1 controls postnatal bone
formation by regulating fibroblast growth factor signaling in
osteoblasts. J Biol Chem 279: 27743–27752.
Xiao L, Liu P, Li X, Doetschman T, Coffin JD, Drissi H, Hurley
MM. 2009. Exported 18-kDa isoform of fibroblast growth fac-
tor-2 is a critical determinant of bone mass in mice. J Biol
Chem 284: 3170–3182.
Xiao L, Sobue T, Esliger A, Kronenberg MS, Coffin JD, Doetsch-
man T, Hurley MM. 2010. Disruption of the Fgf2 gene acti-
vates the adipogenic and suppresses the osteogenic program
in mesenchymal marrow stromal stem cells. Bone 47:
360–370.
Xiao L, Esliger A, Hurley MM. 2013. Nuclear fibroblast growth
factor 2 (FGF2) isoforms inhibit bone marrow stromal cell
mineralization through FGF23/FGFR/MAPK in vitro. J Bone
Miner Res 28: 35–45.
Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD. 2014. Oste-
ocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS One
9: e104154.
Xie Y, Su N, Jin M, Qi H, Yang J, Li C, Du X, Luo F, Chen B, Shen
Y, et al. 2012. Intermittent PTH (1–34) injection rescues the
retarded skeletal development and postnatal lethality of
mice mimicking human achondroplasia and thanatophoric
dysplasia. Hum Mol Genet 21: 3941–3955.
Xu D, Esko JD. 2014. Demystifying heparan sulfate-protein inter-
actions. Annu Rev Biochem 83: 129–157.
Yamashita A, Morioka M, Kishi H, Kimura T, Yahara Y, Okada
M, Fujita K, Sawai H, Ikegawa S, Tsumaki N. 2014. Statin
treatment rescues FGFR3 skeletal dysplasia phenotypes. Na-
ture 513: 507–511.
Yan D, Chen D, Cool SM, van Wijnen AJ, Mikecz K, Murphy G,
Im HJ. 2011. Fibroblast growth factor receptor 1 is principally
responsible for fibroblast growth factor 2-induced catabolic ac-
tivities in human articular chondrocytes. Arthritis Res Ther
13: R130.
Yang F, Wang Y, Zhang Z, Hsu B, Jabs EW, Elisseeff JH. 2008. The
study of abnormal bone development in the Apert syndrome
Fgfr2+/S252W mouse using a 3D hydrogel culture model. Bone
43: 55–63.
Yang L, Tsang KY, Tang HC, Chan D, Cheah KS. 2014. Hypertro-
phic chondrocytes can become osteoblasts and osteocytes in
endochondral bone formation. Proc Natl Acad Sci 111:
12097–12102.
Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura
M, Kurihara T, Rogi T, Tanaka S, SudaM, et al. 2004. Overex-
pression of CNP in chondrocytes rescues achondroplasia
through a MAPK-dependent pathway. Nat Med 10: 80–86.
Yeh E, Atique R, Ishiy FA, Fanganiello RD, Alonso N, Matushita
H, da Rocha KM, Passos-Bueno MR. 2012. FGFR2 mutation
confers a less drastic gain of function in mesenchymal stem
cells than in fibroblasts. Stem Cell Rev 8: 685–695.
Yeung Tsang K,Wa Tsang S, ChanD, Cheah KS. 2014. The chon-
drocytic journey in endochondral bone growth and skeletal
dysplasia. Birth Defects Res C Embryo Today 102: 52–73.
Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J,
et al. 2008. A Pro253Arg mutation in fibroblast growth factor
receptor 2 (Fgfr2) causes skeleton malformation mimicking
human Apert syndrome by affecting both chondrogenesis
and osteogenesis. Bone 42: 631–643.
YokotaM, Kobayashi Y,Morita J, Suzuki H, Hashimoto Y, Sasaki
Y, Akiyoshi K, Moriyama K. 2014. Therapeutic effect of nano-
gel-based delivery of soluble FGFR2 with S252Wmutation on
craniosynostosis. PLoS One 9: e101693.
Yoon BS, Ovchinnikov DA, Yoshii I, Mishina Y, Behringer RR,
Lyons KM. 2005. Bmpr1a and Bmpr1b have overlapping func-
tions and are essential for chondrogenesis in vivo. Proc Natl
Acad Sci 102: 5062–5067.
Yoon WJ, Cho YD, Kim WJ, Bae HS, Islam R, Woo KM, Baek JH,
Bae SC, Ryoo HM. 2014. Prolyl isomerase Pin1-mediated con-
formational change and subnuclear focal accumulation of
Runx2 are crucial for fibroblast growth factor 2 (FGF2)-in-
duced osteoblast differentiation. J Biol Chem 289: 8828–8838.
Yoshida CA, Yamamoto H, Fujita T, Furuichi T, Ito K, Inoue K,
Yamana K, Zanma A, Takada K, Ito Y, et al. 2004. Runx2
and Runx3 are essential for chondrocyte maturation, and
Runx2 regulates limb growth through induction of Indian
hedgehog. Genes Dev 18: 952–963.
Yu K, Ornitz DM. 2001. Uncoupling fibroblast growth factor re-
ceptor 2 ligand binding specificity leads to Apert syndrome-
like phenotypes. Proc Natl Acad Sci 98: 3641–3643.
Yu K, Ornitz DM. 2008. FGF signaling regulates mesenchymal
differentiation and skeletal patterning along the limb bud
proximodistal axis. Development 135: 483–491.
Yu K, Herr AB, Waksman G, Ornitz DM. 2000. Loss of fibroblast
growth factor receptor 2 ligand-binding specificity in Apert
syndrome. Proc Natl Acad Sci 97: 14536–14541.
Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA, Ornitz
DM. 2003. Conditional inactivation of FGF receptor 2 reveals
an essential role for FGF signaling in the regulation of osteo-
blast function and bone growth. Development 130:
3063–3074.
Zeller R, Lopez-Rios J, ZunigaA. 2009. Vertebrate limb bud devel-
opment: moving towards integrative analysis of organogene-
sis. Nat Rev Genet 10: 845–858.
Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eli-
ceiri KW,Keely PJ, LongmoreGD. 2013. The collagen receptor
discoidin domain receptor 2 stabilizes SNAIL1 to facilitate
breast cancer metastasis. Nat Cell Biol 15: 677–687.
Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX. 2000. A
Pro250Arg substitution in mouse Fgfr1 causes increased ex-
pression of Cbfa1 and premature fusion of calvarial sutures.
Hum Mol Genet 9: 2001–2008.
ZhouX, von derMark K, Henry S, NortonW, AdamsH, de Crom-
brugghe B. 2014. Chondrocytes transdifferentiate into osteo-
blasts in endochondral bone during development, postnatal
growth and fracture healing in mice. PLoS Genet 10:
e1004820.
Zhou ZQ, Ota S, Deng C, Akiyama H, Hurlin PJ. 2015. Mutant
activated FGFR3 impairs endochondral bone growth by pre-
venting SOX9 downregulation in differentiating chondro-
cytes. Hum Mol Genet 24: 1764–1773.
Ornitz and Marie
1486 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
 10.1101/gad.266551.115Access the most recent version at doi:
 2015 29: 1463-1486 Genes Dev.
  
David M. Ornitz and Pierre J. Marie
  
disease











Creative Commons License (Attribution-NonCommercial 4.0 International), as described 
). After six months, it is available under ahttp://genesdev.cshlp.org/site/misc/terms.xhtml
six months after the full-issue publication date (see 
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first
Service
Email Alerting
 click here.right corner of the article or




 (133 articles)  Development
 (145 articles)  Cancer and Disease Models
  
Articles on similar topics can be found in the following collections 
 http://genesdev.cshlp.org/subscriptions
go to: Genes & Development To subscribe to 
© 2015 Ornitz and Marie; Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
